CORONA Main Coronavirus thread

Heliobas Disciple

TB Fanatic
(fair use applies)

Washington mask mandate ends March 21
Gov. Jay Inslee announced plans to end the state’s indoor mask mandate on March 21 in most locations, including schools. Masks will still be required in hospitals.
Josh Lyle
Published: 8:53 AM PST February 17, 2022 | Updated: 4:21 PM PST February 17, 2022

OLYMPIA, Wash. — Washington state’s indoor mask mandate has an end date. Gov. Jay Inslee announced that face masks will no longer be required beginning March 21 for most settings, including schools and childcare facilities.

The state will still require masks to be worn in health care environments like hospitals and dental offices. Masks will also be required in long-term care settings and correctional facilities. Federal law also requires masks in certain places like public transportation and school buses.

The state will also drop the vaccine verification requirement for large events starting on March 1.

"We think that’s a very important step in the next part of our journey toward normalcy. I want to thank Washingtonians who have put us in a position to be able to make this progress," Inslee said during the press conference. "We are in a position to be able to make this progress because people have been careful, have by and large followed our mandates, and have been responsible. And most Washingtonians have got vaccinated as well. This is what has allowed us to be in this position to reduce these mask mandates."

Following the end of the mandate, businesses and local governments will still be allowed to implement their own vaccination or mask requirements for employees and customers. School districts can also decide to have students and teachers wear masks.

The state is still working on updated COVID-19 guidance for schools. The governor’s office said the state Department of Health would have more details the week of March 7.

While masks will no longer be required in schools after March 21, districts will still be required to report COVID-19 cases. Students and staff with symptoms of COVID-19 will still be required to quarantine and follow CDC and DOH isolation protocol.

Employers will be required to follow safe workplace protocols, even after the mask mandate ends. Employers must notify workers of potential exposures, and larger employers must report outbreaks to the state Department of Labor & Industries.

Employers must allow workers to wear masks if they choose.

The announcement comes as the spike in COVID-19 cases related to the Omicron variant is on a downward trend. Cases in Washington are dropping quickly, a trend that is expected to continue.

States with indoor mask mandates

Washington is currently one of just five states with an indoor mask mandate still in place. The other states with mandates include Oregon, Hawaii, Illinois, and New Mexico.

Oregon announced its indoor mask requirements would lift by March 31 at the latest. Another state, California, lifted its indoor mask mandate for vaccinated people on Wednesday. Unvaccinated people in California must still wear masks and some counties have kept masking rules in place.

A statewide indoor mask mandate has been in place in Washington since Aug. 23, 2021. An outdoor mask mandate was added in September for events with 500 or more people.

Washington schools defy mask mandate

This week, at least two school districts in Washington voted to make masks optional for students and staff in defiance of the state’s mask mandate. The Washington Office of Superintendent of Public Instruction (OSPI) has warned schools that they could lose state funding if they don’t follow the law.

The warning from Reykdal came after he sent a letter himself to Gov. Inslee last week asking him to remove the mask mandate in schools.

In that letter to the Governor, Reykdal said with high immunity rates and rapid testing available, now is the time to address masking in schools.

Dozens of other districts in eastern Washington sent a letter to Gov. Inslee asking the state to end the mask mandate for schools and move contract tracing responsibilities away from school districts.

Outdoor mask mandate ending

Inslee already announced that outdoor masking requirements will end on Feb. 18. That rule required masks to be worn at large outdoor events.

The state will also remove the requirement that hospitals postpone non-elective surgery on Feb. 18 and end hospital assignments for National Guard members.

Hospital visitor policies

As COVID-19 cases begin to trend downward in Spokane County, Providence Health Care announced that they will be updating their visiting policy for Providence Ministries in Spokane and Stevens counties. According to Providence, as of Thursday, Feb. 17:
  • All non-COVID adult inpatients in hospitals and medical centers may have one visitor per day.
  • Adult outpatients who have appointments at the hospital or clinic may have one support person.
  • All non-COVID laboring inpatients may have one support person and one visitor during labor and birth process.
 

naegling62

Veteran Member
Does anyone have Dr. Geert Vanden Bossche's website? I had to get a new phone and when I search on Google for his website nothing comes up.
 

BUBBAHOTEPT

Veteran Member
Something MOST definitely is going on, so why does it give me the willies?
It gives us all the willies. We have have been lied to and have seen such a distortion of statistics that anything They do is suspect... :kaid:
Like Pfizer giving the word to their FDA toadies to slow their role on vaccinating 5 year olds and below. Something is definitely not right, and my God, you could go in all kinds of directions from that one move alone… :hmm:
 

jward

passin' thru
BNO Newsroom
@BNODesk

6m

Biden extends national emergency for COVID-19, says the pandemic continues to cause significant risk to public health and safety
Biden to extend U.S. national emergency due to COVID-19 health risk
February 18, 20226:16 PM CSTLast Updated 6 hours ago

2-3 minutes


U.S. President Joe Biden delivers remarks on his administration's efforts to pursue deterrence and diplomacy in response to Russia’s military buildup on the border of Ukraine, from the White House in Washington, U.S., February 18, 2022. REUTERS/Kevin Lamarque

Feb 18 (Reuters) - President Joe Biden said on Friday the U.S. national emergency declared in March 2020 due to the COVID-19 pandemic will be extended beyond March 1 due to the ongoing risk to public health posed by the coronavirus.
Biden said the deaths of more than 900,000 Americans from COVID-19 emphasized the need to respond to the pandemic with "the full capacity" of the federal government.
Former President Donald Trump had declared a national emergency almost two years ago to free up $50 billion in federal aid.

"There remains a need to continue this national emergency," Biden said in a letter on Friday to the speaker of the House of Representatives and the president of the Senate.
The letter was released by the White House.
The emergency would have been automatically terminated unless, within 90 days prior to the anniversary date of its declaration, the president sent a notice to the Congress stating it is to continue beyond the anniversary date.
Biden's step to extend the emergency comes even as a slew of local leaders in the United States are dialing back pandemic restrictions as the Omicron wave ebbs. read more

The governors of New York and Massachusetts announced last week that they would end certain mask mandates in their states, following similar moves by New Jersey, California, Connecticut, Delaware and Oregon.
U.S. health officials said earlier this week they were preparing for the next phase of the pandemic as Omicron-related cases decline. read more

Reporting by Kanishka Singh in Bengaluru; Editing by Will Dunham and Sandra Maler
 

Heliobas Disciple

TB Fanatic
(fair use applies)

South African doctor who discovered Omicron refuses to 'create fear' by hyping variant's threat
Angelique Coetzee asked her secretary to "give me another Nexium" to deal with the international pressure she was facing to deem COVID variant worse than South African doctors were seeing.
Greg Piper
Updated: February 18, 2022 - 10:30pm

"I cannot make a disease worse, and create fear out there," says Dr. Angelique Coetzee, the South African doctor who discovered Omicron.

In an interview on Just the News Not Noise, Coetzee, chair of the South African Medical Association, described the pressure she faced from public health authorities worldwide to portray the now-dominant variant of COVID-19 as more severe than she was witnessing in real time.

"I said to my secretary, 'Just give me another Nexium,'" she recalled, referring to a medication that reduces stomach acid. "That's how I survive" and "stick to my guns."

She declined to name which officials were particularly bearing down on her to conform South Africa's first-in-the-world experience with Omicron to the international narrative that any new variant would be deadly.

Coetzee previously said "all of these scientists and politicians who aren't from South Africa were contacting me telling me I was wrong" when she publicly described typical Omicron symptoms as "a bit of a headache" and "more of a scratchy" throat.

"I'm not going to put my head into that hornet's nest" by naming the international heavyweights who put politics over science, she told the podcast. "They know what they said ... unfortunately, we all have to work together."
Coetzee believes that scientists, "especially in the beginning," were frightened by Omicron "because all they saw was the mutations and the immune escape possibility."

When she and her colleagues started to refer to the variant as "a mild disease, we were told, 'You cannot say it's a mild disease, it's a severe disease, look at the mutations. And it's too early ... You should not say it out there.'"

She's not saying "it's not a severe disease for people with comorbidities" or for those who are unvaccinated. "They could still die from it," Coetzee told the podcast. "But for the majority of people, it's a mild disease, and I refuse to change the story."

The doctor was not simply describing her own patients. In the first three weeks observing Omicron, "I kept on checking with all the doctors in South Africa," especially general practitioners, she recalled.

"Every day we spoke," and she asked whether others saw "a different pattern" or more admissions, Coetzee said. "They kept on telling me ... there's no overflow of patients."

This was a surprise, as was the timing of Omicron, which the doctor said arrived "a whole month too early" given previous waves. Her first thought: "Please, not now."

They were still thinking in terms of the "very scary" Delta variant, but the symptoms turned out to be completely different.
"The first seven patients that I saw on the same day, we started to treat them exactly the same as with Delta, as we didn't know," Coetzee recounted. "And it took me around about four or five days to start to realize that the symptoms are much milder," with safe at-home treatment, "no need for oxygen" and apparently no "cardiovascular side effects." Instead patients had "myalgia, muscle aches and pains, headaches, low back ache, or intercostal pain."

At that stage, they alerted authorities and took another five days to confirm this was a new variant. But the high number of mutations was all they cared about, and futile travel bans soon followed.

"The virus is everywhere, loves to travel," Coetzee said, and COVID testing wouldn't catch early infections in those who were flying abroad. "It's like a storm in a teacup ... It's already there. You just didn't know it."

She emphasized the value of South Africa's experience for international COVID policy, since the country "started to vaccinate only in our third wave."

Regardless of vaccination, recovery from infection or both, "the chances that you can get mild disease is quite quite high," Coetzee said, but unvaccinated patients are more likely to have the severe end of mild symptoms, such as headaches and fatigue.

"We do see that in our ICUs, 80% are unvaccinated," she said, while those who are vaccinated, especially older than 50 with comorbidities or conditions such as lupus, will be "much more safer."

While she credited face masks, social distancing and hand-washing for a decline in "normal upper respiratory tract infections" in South Africa, Coetzee warned that people should only wear "clean" masks and replace them regularly. "Otherwise, it becomes a bacterial trap for yourself and trap for other viruses."

She's not confident that the world will ever know where COVID originated, or "whether it was tampered with. ... We'll have to learn to live with it. I don't think it's really going to go away."
.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

EXCLUSIVE: Former Harvard Prof. Martin Kulldorff: ‘Science and Public Health Are Broken’
By Charlotte Cuthbertson
February 16, 2022 | Updated: February 18, 2022

Dr. Martin Kulldorff is one of the most qualified public health pandemic experts in the United States. To the narrative-shapers, he’s a pariah.

As a prominent epidemiologist and statistician, Kulldorff has worked on detecting and monitoring infectious disease outbreaks for two decades. His methods are widely used around the world and by almost every state health department in the United States, as well as by hundreds of people at the Centers for Disease Control and Prevention (CDC).

Kulldorff has also worked on vaccine safety for decades, developing globally used methods for monitoring adverse reactions in new vaccines.

His résumé on the Food and Drug Administration (FDA) website is 45 pages long and includes a list of 201 peer-reviewed published journal papers. His work has been cited more than 27,000 times.

Since 2003, Kulldorff worked at Harvard Medical School, first as an associate professor of population medicine and later as a professor of medicine.

In November, Harvard and Kulldorff abruptly parted ways.

Kulldorff prefers to keep the reasons private, but it’s hard to ignore that he placed himself in the crosshairs of the pandemic narrative early on in the “15 days to slow the spread” lockdown and has since paid the price.

It’s quite something for a public health scientist at the top of his game to admit that “both science and public health are broken.”

“For some reason, a public official narrative was established, and you weren’t allowed to question it—which, of course, is very detrimental, both to the pandemic and how to deal with the pandemic, because you have to have a vibrant discussion to figure out how best to deal with these things,” he told The Epoch Times.

The Swedish native said he tried to point out in March 2020 that there was a very steep age gradient on mortality for COVID-19, the disease caused by the SARS-CoV-2 virus.

Kulldorff said he attempted to publish a paper both in U.S. medical journals and mainstream newspapers stating that while anyone could contract the virus, the focus should be on protecting the elderly and those at high risk. His paper was knocked back from all directions.

“I was able to publish in Sweden, in the major daily newspapers there during the spring of 2020, so that was not a problem,” he said. “But the United States was not allowed to have a debate, which is very troubling.”

The Great Barrington Declaration

His early efforts culminated in the Great Barrington Declaration, published with Dr. Sunetra Gupta and Dr. Jay Bhattacharya in October 2020. The declaration called for a more nuanced approach to the one-size-fits-all restrictions that had been imposed on much of Western society.

“The most compassionate approach that balances the risks and benefits of reaching herd immunity, is to allow those who are at minimal risk of death to live their lives normally to build up immunity to the virus through natural infection, while better protecting those who are at highest risk,” the declaration states.

The two other authors are also amply qualified in the field. Gupta is a professor at Oxford University, an epidemiologist with expertise in immunology, vaccine development, and mathematical modeling of infectious diseases. Bhattacharya is a professor at Stanford University Medical School, a physician, epidemiologist, health economist, and public health policy expert focusing on infectious diseases and vulnerable populations.

Kulldorff said the Great Barrington Declaration proposed nothing new.

“It’s just the basic fundamental principles of public health that existed in the pandemic preparedness plan that was prepared many years before,” he said. “It’s sort of astonishing that it wasn’t followed from the very beginning of the pandemic.”

Conventional public health science had deemed it unnecessary and potentially harmful to close schools and small businesses, to impose masking on the general public, and to quarantine healthy people.

Kulldorff said the document wasn’t for the politicians, or scientists, or even the doctors—although thousands of each signed it.

“The most important audience was the public,” he said, “because it’s the public that ultimately will end these misguided public health policies. It’s the public, regular people, who are suffering the consequences.”

He said the authors wanted to advise the average person that their intuition was correct, that the restrictions weren’t based on public health science—”so when you oppose them, you’re standing on firm scientific ground.”

“The key thing was to break the pretense that there was scientific consensus for these lockdowns—which there wasn’t.”
The appearance of a scientific consensus was formed through high-profile public health officials such as Dr. Anthony Fauci, Dr. Francis Collins, and Dr. Deborah Birx, as well as corporate media along with the stifling of opposing viewpoints.

“There’s really no public health arguments against the declaration. So if you want to criticize it, you have to … make up lies about it and then attack that, as well as slander the people behind it. And they did both of those things,” Kulldorff said.
It wasn’t until a December 2021 email dump that Kulldorff and the American public got to peek behind the curtain of how the traditional pandemic playbook had been tossed and how swiftly dissenting voices were maligned.

Following a Freedom of Information Act request, emails that involved Fauci, the director of the National Institute of Allergy and Infectious Diseases (NIAID), were released. An email to Fauci from Collins, then-director of the National Institutes of Health, was sent days after the Great Barrington Declaration was published.

“This proposal from the three fringe epidemiologists … seems to be getting a lot of attention,” Collins told Fauci in the Oct. 8, 2020, email. “There needs to be a quick and devastating published takedown of its premises. I don’t see anything like that online yet—is it underway?”

Collins’s four-line email mentioned that the declaration included “even a co-signature from Nobel Prize winner Mike Leavitt at Stanford.”

Fauci appears to have been in full agreement with Collins’s proposal to take down the authors and their declaration, sending a one-line reply.

“I am pasting in below a piece from the Wired [magazine] that debunks this theory,” he wrote. Collins replied. “Excellent.”
Within a day of the Collins–Fauci exchange, Google began to censor search results for “Great Barrington Declaration.”
In a subsequent interview, Collins said the declaration “is not mainstream science. It’s dangerous.”

Fauci called the declaration “ridiculous” and “total nonsense” in an interview with ABC.

A cavalcade of articles from corporate media outlets ensued, with a common theme to disparage the declaration and its authors.

The New York Times called focused protection a “viral theory.”

BuzzFeed called it a “highly controversial recommendation.”

Forbes called the declaration’s detractors “real infectious disease and public health experts.”

“Anti-lockdown advocate appears on radio show that has featured Holocaust deniers,” a Guardian headline blared, referring to Kulldorff’s interview on the “Richie Allen Show.”

Gregg Gonsalves, an associate professor of epidemiology at Yale, called the focused protection strategy “a massacre” and a “straw man argument” produced by “fancy scientists,” in a Twitter thread a week after the declaration was published.

Kulldorff, when asked if he’d ever considered himself a “fringe epidemiologist,” said, “No I have not, but I guess, when the public health leaders get it wrong, then it’s an honor to be a fringe epidemiologist.”

Social media giants such as Twitter and Facebook jumped on the censorship bandwagon and started labeling certain posts as misleading, while permanently banning journalists such as Alex Berenson.

Berenson’s final tweet before being purged was about the COVID-19 vaccines.

“It doesn’t stop infection. Or transmission,” he posted on Aug. 28, 2021. “Think of it—at best—as a therapeutic with a limited window of efficacy and terrible side effect profile that must be dosed in advance of illness. And we want to mandate it? Insanity.”

Berenson, a former New York Times journalist, has since sued Twitter.

“You always have to be allowed to question science,” Kulldorff said. “We should never silence that debate, pretend that there’s some person who is ‘The Science,’ who has all the truths.

“I think that happened during this pandemic and that’s an embarrassment for the scientific community.”

In an interview at the end of November 2021, Fauci lashed out at Republican senators who had criticized him.

“They’re really criticizing science, because I represent science,” Fauci told CBS.

Personal Life

Kulldorff was 8 years old when he first came to reside in the United States. His father, also a scientist, moved the family from Sweden for a one-year university sabbatical in 1970.

It was October, and two weeks after arriving in Texas, Kulldorff’s mother told him to don a costume and head out with the local children.

“We walked around the neighborhood, and everywhere we knocked on the door, they gave us candy. So that was pretty nice for an 8-year-old. And I’ve liked this country ever since,” he said.

Kulldorff returned to the United States for a couple of years in the 1980s for his doctoral work, and in the early ’90s, he made the move permanent.

The original dream for Kulldorff was to teach high school math and history. He laughs about it still being a backup plan if his current career falls apart.

He still sees fatherhood as his most important job. As a single father with a 19-year-old son and twin 6-year-olds, he spends a lot of time with his children.

“I think the most wonderful and the most important thing in life is to be a parent and see your children grow up,” he said. “So I have always spent plenty of time with them since they were born. I’ve always prioritized that over my career.”

He said the twins were fortunate during the pandemic restrictions in Connecticut to have each other as built-in playmates.
His oldest son was 17 when the pandemic started.

“I wasn’t concerned about him getting COVID because I knew that the risk for him is minuscule. But I was very concerned about his mental health. So I was urging him to go out there and play basketball with his friends, hang out with them, do those social things. I wanted him to have as normal a life as possible.”

Why Take a Stand?

Kulldorff has worked in both the Swedish and U.S. health science fields, and followed closely his native country’s very different, less invasive response to the pandemic.

His family members in the Nordic country understood when he took a divergent tack to the U.S. mainstream narrative of harsh lockdowns, closing schools, and mandatory masking.

“Sweden had a more sane approach to it, so they didn’t find it strange what I was saying,” he said.

He didn’t set out to be a rebel, and there wasn’t much hand wringing behind Kulldorff’s decision to go against the grain when he saw the tried-and-true pandemic response being cast aside.

“I don’t think I have a choice. Since I worked on infectious disease outbreaks for two decades and they instituted policies that go against the basic principles to public health, I can’t just be silent. I have to speak up. There’s no other alternative,” he said.

“Otherwise, what’s the point of being a public health scientist?”

He’s quick to show support for other scientists who agree with him but feel as if they can’t speak out due to potential loss of research funding or even their job. People such as Fauci, who oversees an annual taxpayer-funded budget of over $6 billion at NIAID, hold the purse strings as well as control of what’s published in journals.

“If you dare speak out against [Fauci’s] views on the pandemic, you can lose funding. And if you agree with him and support him, you can gain funding,” Kulldorff said.

Four prominent scientists who were instrumental in shaping the COVID-19 “natural origin” narrative received substantial increases in grant money from Fauci’s NIAID in the subsequent two years, The Epoch Times found.

“So I fully understand that scientists are very afraid of criticizing the policies championed by the guy who sits on the biggest chunk of infectious disease research money in the world,” Kulldorff said.

“We shouldn’t have those conflicts. Research should be very broad, and we should fund broadly different ideas, and some pan out and some don’t, but that’s how you do good science.”

Collateral Damage

One of the major precepts behind the Great Barrington Declaration is that public health is wide-ranging and needs a long-term view, yet many influential scientists had a singular focus on COVID-19 outcomes.

“One of the principles of public health is, it’s not about one disease, like COVID, it’s about all of public health,” Kulldorff said.

That singular focus resulted in government officials filling skateboard parks in California with sand and locking up children’s playgrounds with chains and yellow police tape. Millions of children were sent home from school and for almost two years were forced to learn virtually from home.

Meanwhile, teen suicide rates have increased, drug and alcohol abuse has increased, domestic violence has risen, while childhood vaccinations decreased and cancer screenings plummeted.

Health experts warned in May 2020 that as pandemic-driven hardship puts added strain on the mental health of Americans, as many as 154,000 extra lives may be lost due to drug or alcohol abuse and suicide, or “deaths of despair.”

People were dying from cardiovascular diseases that, in normal circumstances, they would have survived, Kulldorff said,”because maybe they were afraid to go to the hospital, or they went too late.”

“So these are all tragic consequences, collateral damage, of these COVID measures, restrictions that were imposed,” he said. “And you can’t just do that for a whole year or two and expect that it doesn’t have other enormously bad outcomes on public health.”

Kulldorff anticipates that many of the ancillary health impacts have yet to surface.

In January, a Johns Hopkins meta-analysis of lockdown data concluded that lockdowns didn’t save lives.

What’s Next?

Kulldorff is dedicating his next chapter to helping restore trust in science and public health—both of which he calls “broken.”

“So it’s the heads of the funding agencies, the heads of the big journals, and the university presidents and deans who all went into the same bubble thinking that they knew what was right, and which turned out to be wrong,” Kulldorff said.

“But all scientists now are going to have to suffer from that, because, for good reasons, the public won’t trust scientists anymore.”

He’s working with the Brownstone Institute as the scientific director to navigate how to shore up public health again. He’s also part of Hillsdale College’s new Academy for Science and Freedom, which he says will promote and defend the importance of open, free scientific discourse.

“It’s very clear that if we want to have vibrant science, and a vibrant scientific community, we have to reform the way science operates and the way public health operates,” he said.

But, Kulldorff said, it’s up to the public—the truckers, farmers, nurses, pilots, and parents—as well as rank-and-file scientists to effect real change.

It’s also time to compassionately help each other heal from the psychological and mental wounds, he said, especially those still living in constant fear of COVID and those who have been self-isolating for two years now.

“I think we shouldn’t blame those who were afraid, because they were major victims of this pandemic strategy,” he said.
“We shouldn’t blame people for believing Anthony Fauci and the CDC—that was the natural thing to do. We just have to help them realize that these measures were misguided so that never happens again.”
 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=Asoue_J2BHI


TWiV 868: COVID-19 clinical update #102 with Dr. Daniel Griffin
Feb 19, 2022
47 min 24 sec

In COVID-19 clinical update #102, Daniel Griffin reviews children and COVID, effectiveness of maternal vaccination, vaccines for immunocompromised, primary care physicians and vaccination rates, booster safety among adults, placentitis, azithromycin, oral Nirmatrelvir, Omicron antibody evasion, EUA for bebtelovimab, IL-1 blocking agents, thromboprophylaxis, effectiveness of vaccines against long COVID, and risks of mental health outcomes. Show notes at https://www.microbe.tv/twiv/twiv-868/
 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=qfcSGoTUu7Y


Prevalence remains high
Feb 18, 2022
16min 22sec

The release of the California SMARTER Plan: The Next Phase of California’s COVID-19 Response It is clear the virus will remain with us for some time, if not forever. However, we know what works, and have built the necessary tools over the last two years that allows us to learn and hone our defenses to this virus as it evolves. As we enter the next phase with COVID-19, which may include future surges and new variants, In our approach to this next phase, we will be smarter than ever before, using the lessons of the last two years to approach mitigation and adaptation measures This includes vaccines, masks, tests, quarantine, improving ventilation, and new therapeutics. But California’s path forward will also be predicated on our individual, smarter actions, that will collectively yield better outcomes for our neighborhoods, communities, and state. [...]
 

Heliobas Disciple

TB Fanatic
(fair use applies)

Horowitz: The lies about vaccine efficacy are exposed, so Scotland stops publishing data
Op-ed
Daniel Horowitz
February 18, 2022

If the truth hurts your narrative, you must censor it. But what if your own information harms your own narrative? Well, then you stop publishing it.

For the past few months, Scotland has been publishing age-stratified case rates by vaccination status in a very well broken-down chart every Wednesday afternoon, similar to the way the U.K. published the data every Thursday. The common thread observed from these trends was that the unvaccinated had the lowest case rate, the double-vaccinated had even higher death and hospitalization rates, and the triple-jabbed gradually had increasingly higher case rates, which clearly doesn’t portend good news even for hospitalization and death in the long run. When people like me started using their data, we were lambasted by the “fact-checkers” paid for by Big Pharma. Now Scottish health officials announced they will not be publishing the data at all.

“Public Health Scotland will stop publishing data on covid deaths and hospitalisations by vaccination status — over concerns it is misrepresented by anti-vaxx campaigners,” reports the Glasgow Times.

The notice of change was published on page 29 of the latest, and evidently final, Wednesday report from Feb. 16. “PHS is aware of inappropriate use and misinterpretation of the data when taken in isolation without fully understanding the limitations described below,” they decried.

You mean like screenshotting their own charts?

Obviously, there can be confounding factors, but those factors actually cut both ways. However, at the end of the day, these are age-stratified adjusted case rates per 100,000 and are completely fair game to use. No vaccine that is anywhere near as effective as they make it out to be should be netting these results.

Here is the latest case rate chart from the final report:

img.png


As you can see, for the past two weeks they have been placing disclaimers at the bottom of the charts.

What the chart clearly shows is what we have been seeing throughout the world — from the U.K., Canada, and Israel, for example — namely, that the second shot has gone negative a long time ago and the third shot is gradually following in the same direction. The public health officials themselves are demanding that people get boosters because they say the other shots wane. Well, logic would dictate that now that we are three to five months into the boosters in most places, they are waning as well. We also know that waning efficacy is potentially associated with a Trojan horse effect of antibody dependent disease enhancement, something the FDA admitted was never studied in the long run (at the time they thought the shots wouldn’t wane) but would be a risk “potentially associated with waning immunity.”

The main argument of those who are against us screenshotting their own charts to point out what they themselves have admitted is a speculative theory that perhaps the vaccinated test more often than the unvaccinated. That is a purely speculative confounding factor in the favor of the vaccine, but here is a concrete proven confounder against the vaccine: Scotland counts the first 21 days of the first vaccine as unvaccinated and the first 14 days of the third vaccine as double-vaccinated. We already know from Alberta’s data (which of course they also took down since we cited it) that roughly 40% of cases, 47.6% of hospitalizations, and 56% of deaths among the vaccinated occurred within 14 days of vaccination! So if anything, many of the cases and deaths ascribed to the unvaccinated are caused by the immune suppression of the first shot, and many cases and deaths ascribed to the double-vaccinated makes that cohort look even worse than it already is in order to ameliorate the image of the boosters.

Furthermore, if the higher case rates among the vaccinated are the result of a higher testing rate, then why would the double-vaxxed also be worse off than the unvaccinated for hospitalizations and deaths, as PHS has been showing for weeks in its other charts?

img.png


It’s quite evident that everyone is tested in the hospital. If anything, it stands to reason that the unvaccinated would be more aggressively tested even when admitted for other ailments and therefore potentially be roped into incidental hospitalization counts more often than the vaccinated. For example, in June 2021, Scripps Health in San Diego announced it would only test unvaccinated asymptomatic patients but not the vaccinated. Clearly, the testing requirements of the unvaccinated and the counting of the (immune-suppressed) partially vaccinated as unvaccinated would be confounding factors for woefully overestimating unvaccinated hospitalizations, not the other way around.

Also, why would the triple-vaxxed test less often than the double, who test more often than the single or unvaccinated? And why would the waning always continue in the same direction throughout the pandemic? As you can see from the U.K. Health Security Agency weekly reports, the efficacy of the shots constantly wanes with every new weekly report, a phenomenon that cannot be explained away by testing rates.

Infection rate growth (Rept Wks 50 to 7) since Omicron became dominant is much higher in all boosted cohorts. In boosted adults \u226550, growth increases sharply with age or time since boosting - whereas infection rate growth in the unvaxxed is more consistent across cohorts. Why?pic.twitter.com/DhQ2r9wlcz
— Don Wolt (@Don Wolt)
UKHSA COVID Hospitalization Update: 2/17/22\n\nWeek 7 report just came out.\n\nBefore and After % of Total Hosps by Age Group by Vax Status (dose).\n\nChart 1 - Week 6 Report\nChart 2 - Week 7 Report (current)\n\nIf anyone knows where to locate Pop Vax% by Age group, please show me.\n\n/1pic.twitter.com/ZXIVVfpCFp
— Hold2 (@Hold2)
Clearly, this picture points to dangerous waning efficacy that plagues every cohort within a few months.

The bottom line is that during the final week of reporting in Scotland, just 12% of the deaths are among the unvaccinated, and that is including the 21-day grace period of counting the single-jabbed as unvaccinated. Nobody is suggesting that there is no efficacy for some people for a period of time against serious illness before the shots wane. But to suggest that this is a pandemic of the unvaccinated, to ignore the negative efficacy on infection which has been true across the board since last summer, and to obfuscate the concern of waning efficacy on critical illness even as they themselves demand boosters defies willing suspension of disbelief.

Unbelievably, PHS admits that the shots first suppress the immune system before they ramp up antibodies. But instead of using this as a strike against the shots, they use that is a strike against the unvaccinated and assert that it is a factor for why you can’t even compare hospitalization or death rates. “Individuals who have not completed their vaccine schedule may be more susceptible to a severe outcome and could result in higher COVID-19 case, hospitalization and death rates in the first and second dose vaccine groups,” claims PHS in the report.

But if that is true, that is the fault of the manufacturers who made a shot that first makes you vulnerable during an ongoing pandemic. It’s one thing to have a shot that makes you more vulnerable for a few weeks during the off-season of a virus. But to do so during the pandemic is akin to telling someone in a foxhole during a firefight that they will be safer in a bunker 100 yards ahead but must first run across the field to get there. The risk of making that run should be counted against the bunker option, not the foxhole.

In other words, as I wrote in my original piece on the Scottish data that was “fact-checked,” “You have to look in totality where we are headed rather than manipulating a snapshot of time.” You can’t just pull out one period of time of some efficacy for some people. You need to consider the following:
  • Vaccine injuries short term and long term, known and unknown;
  • Other safer treatment options for COVID itself;
  • A leaky vaccine that wanes in efficacy and runs the risk of enhancing the virus itself even while offering temporary protection for some;
  • The cost to the immune system of constantly boosting people to deal with the abovementioned concern of waning efficacy and enhancement.
The bottom line is that the social media guardians are looking at a snapshot of time. If they were to study the trajectory and progression of the virus and the vaccine throughout the year, they would recognize an unmistakable pattern of waning and then negative immunity. A large study published in the New England Journal of Medicine by Weil Cornell Medicine-Qatar found (table 3) that the Pfizer vaccine waned very quickly after four months. By seven months, when adjusted for those in Qatar who already had prior infection, the Pfizer shot was -4% effective against transmission and just 44.1% effective against severe illness. Also, effectiveness against asymptomatic infection was -33% after seven months.

A Swedish preprint study in October 2021 looked at 1.6 million people in Sweden to examine infection rates and critical illness rates by vaccination status. They found a sliding scale of efficacy that wanes with time, but eventually turns negative. Here is a presentation of fully adjusted vaccine effectiveness against symptomatic infection for various demographics after 210 days:

img.png


Clearly, it was known early on that the vaccine wanes and has the potential to go negative even with Delta, for which both natural infection and the vaccines offered better immunity. It stands to reason that this is certainly the case with Omicron, making it abundantly clear that the negative efficacy rate has more to do with potential Trojan horse antibodies than it does with vaccination-status bias of testing rates.

So what’s the solution? Go for a fourth and fifth shot? This week, Israeli researchers published a preprint study on the efficacy of the fourth shot, which found that after just one month, Pfizer’s shot is down to 30% efficacy and Moderna is down to 11%. At the same time, “Local and systemic adverse reactions were reported in 80% and 40%, respectively.” They conclude, “Low efficacy in preventing mild or asymptomatic Omicron infections and the infectious potential of breakthrough cases raise the urgency of next generation vaccine development.”

Remember, the FDA's industry guidance for EUA status (p. 13) requires a 50% threshold of efficacy to even get emergency use authorization, much less full approval!

Thus, who is actually misreading or inappropriately using data here?

The Israeli study also concluded that “most of these infected HCW [health care workers] were potentially infectious, with relatively high viral loads. Thus, the major objective for vaccinating HCW was not achieved.” Full stop. The biggest public policy debate is over the fact that somehow you not getting the shot affects other people. Here we see that even people with four shots were still infectious with high viral loads. To what degree the shot offers some degree of protection from serious illness for some people for some period of time should be a decision left to the people. Perhaps other people would like to choose therapeutics that offer protection that don’t run the risk of severe adverse reactions. But none of that should have bearings on another human being, and none of that should justify human rights violations.

This entire saga began with censorship of the work of others because the narrative assertions could not withstand peer review. Now we’ve come full-circle, in which the governments’ own data must be censored because the narrative assertions cannot withstand the scrutiny of their own data.
.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

I Will Not Force a Medical Treatment on Anyone
By Laura Van Luven
February 18, 2022

I’ve always loved the holidays, but last year was bittersweet. As 2021 came to a close, I walked away from a comfortable career where I once did good in the world. Unsure of how we would make ends meet and wondering if I’d just made a huge mistake, I knew only that I couldn’t continue working in Public Health.

Since graduating from nursing school in 2008, I’d dreamed of being in this field. I thought of Public Health as a noble mission that made peoples’ lives better, improving the overall health of individuals, families, and communities. I was drawn to this broad, holistic approach. After a decade of working overseas, I found a position with a Minnesota public health agency focused on maternal and child health. For the first couple years, it was almost exactly as I’d hoped. But when the pandemic hit, I saw a totally myopic focus on one respiratory illness and a near complete disregard for any other aspect of health.

For the first time in my career, I was told to ignore suffering and forget best practices. Every day, I felt like a fraud.

My first two years on the job were not without their frustrations, but I loved what I did. As a family health nurse, I visited new mothers and infants that our agency had deemed at risk. I was proud of the relationships I formed and humbled when parents allowed me into their homes. I saw people who lived on a knife’s edge economically, socially, and psychologically. They trusted me with some of their deepest fears.“Is my baby ok? Am I a good enough parent? How will we get by?” I was in awe of my clients who stood in the face of poverty, loneliness, uncertainty, and fear but worked hard and sacrificed everything for their infants. Whether I was helping a new mother to breastfeed, find English classes, muster the courage to call a therapist, or access a food pantry, I felt grateful to be doing this work.

In March 2020, as rumblings of the pandemic picked up, I overheard the nurses commenting that the public schools were closing indefinitely. I thought about the families on my caseload that had kids in school. How would they manage without special education services, how would they manage with work? Many parents didn’t speak much English; did they know what was going on and how to find help? What about kids on free/reduced price meals? “But we know that this virus is not deadly for kids,” I said to one of them. “I know, but they can spread it to the teachers,” one nurse responded. My heart sank and I got a pit in my belly that has been there ever since.

The epidemiologist on staff explained the concept of “flattening the curve” by drawing a graph in blue marker on a white board in the conference room. I suspect it’s still there to this day. Who would see it? Everyone was sent home.

We were told not to come into the office except to pick up any needed supplies and to stay 6 feet away from others when we did. We were to schedule ‘phone visits’ with our clients and check in on them virtually. I spent my final day of in-person work furiously searching for essentials to give my families who couldn’t afford “stocking up.”

From the abrupt halt of home visiting and the laughable direction that we counsel new mothers and assess infants online to vaccine mandates that bred mistrust and fear, I watched my vulnerable families founder and fail. Throughout 2020 and then in late 2021, I voiced my concerns to leadership about the loss of trust in public health. “Harm will happen,” I was told. “Public Health addresses the immediate physical danger first, then deals with the repercussions.”

I watched for 18 months as our new ‘public health’ policies exacerbated inequality, drug abuse, child endangerment, and mental illness. My director responded by accepting more grant money to address these very issues. I was implementing policies that negatively affected the poor and racial minorities while our agency was declaring racism a public health crisis and receiving dollars to fight it. I was helping to trap people in isolation and despair while a coworker wrote about the impending mental health crisis and won a grant from the American Rescue Plan.

I was watching our agency coerce people to take vaccines, which severely decreases trust, and then use federal grant funds to address vaccine hesitancy. While the families I saw were losing their livelihoods, my director was posing for pictures with the governor who enforced the closure of their workplaces. Tolkien’s character Galadriel reminds us, “The hearts of men are easily corrupted.”

One family that I had been working with for over a year was already on the edge of isolation and poverty. The mother stayed home with the four kids, including two young babies, while the dad worked a minimum wage job. They had recently become US citizens and were taking a shot at the American Dream. Their two elementary school-aged children were now home, and mom had to find a way to feed them breakfast and lunch. She did not read English and did not understand she could still access school meals. The school district required families to be physically present at the school and provide proof that they were residents of the district — each day — in order to take home meals. For a woman with 4 small children and no access to a vehicle, this was impossible.

I emailed the school to ask if I could vouch for the family and deliver the meals for the kids. I was denied. The family went without until the father was completely without work and now had the time to go and pick up the meals.

Many of the families I served were undocumented immigrants and unable to file for unemployment or rent assistance. Most lost their income overnight. Head Start closed, forcing low-income parents to leave children with unlicensed childcare providers so that they could attempt to find a new job in an “essential” industry.

One mom told me her 18-month-old would cry when she left him with an old lady in an apartment full of kids. He seemed ‘different’ ever since she started leaving him there, but didn’t feel she had any other choice. As these children were placed in potentially unsafe situations, many in the laptop class would remark to me that they enjoyed the cost savings of not having to put their kids in full time daycare.

It was no surprise to me when the American Academy of Pediatrics declared a national emergency of pediatric mental health in October 2021. Many who work closely with children felt as though we were screaming into the void that this would happen and were just met with the response “children are resilient.” People had confused resilient with adaptable. Children will adapt to any environment they are placed in, including toxic ones. This does not mean they are innately resilient; the problems often manifest in adulthood, particularly when they come to have their own children. The current sharp decline in the mental health of children is only the tip of the iceberg of what is to come.

One family I worked with had 5 children, 4 of whom had special needs. Their mother was single and relied on special-ed services at the school. When the schools closed, she became a prisoner in her own home. She was unable to leave because she could not handle that many children in public by herself. Her mother used to help, but was at high risk for Covid complications and stayed away for many months. She told me that to use her WIC and EBT she would park in front of grocery stores and beg the workers to take her card and use her PIN in order to pay for her groceries.

Summer came and she was unable to take her kids outside because the one who was nonverbal would run through the neighborhood. I called her every week for nearly a year and I would hear the desperation in her voice. She would yell at the kids in the background and tell me she felt like she was going crazy; her children had been without therapies for months. She tried to get online counseling for herself, but it was hard to find the space in her home for privacy.

Another mother had struggled with suicidal ideation and major depression for years. She had a difficult time making it to her counseling appointments. At one point when I called her, she told me she had been in the bathroom the week prior with a bottle of pills. Thinking about her children caused her to put it down. I thanked her for her courage and we came up with a plan and made an appointment with her psychiatrist. Then I hung up the phone and cried. When I caught up with her a few months later, she told me that she had turned to drugs to cope. With 3 young kids, one of whom would later be diagnosed with autism, she was overwhelmed when their Head Start program closed.

Families were terrified of catching Covid and some skipped appointments for themselves or their children because they perceived clinics as dangerous. I discovered later that one family was refusing to allow their boys, ages 6 and 8, outside to play because of the fear of catching Covid from the air. They stayed in the small, cluttered apartment for many weeks watching TV and playing video games. When I saw them in summer, they had gained significant amounts of weight. One mother described symptoms of mastitis and I pleaded with her to go to urgent care but she refused because she was too afraid of Covid. Another young mother would not take her child to get his 18-month vaccines because of a fear of contracting Covid. I tried to explain that pertussis is far more dangerous to her child, but the fear had taken root.

I had always understood that the role of Public Health was to give accurate information to the public and support them in making healthy choices. We were supposed to use facts and data to dispel fear. But now, Public Health began to routinely distort and exaggerate data to fit their narrative. Emails between the Minnesota Health Department and Governor Walz’s staff appear to do just this. The communications director at our own local agency asked us to find a young healthy person who had ended up hospitalized in order to illustrate the dangers of Covid to young people. Since the actual dangers to young healthy people were quite rare, we never found anyone in our community to fit her profile. But someone else did.

How could I convey to the mother with mastitis that the urgent care was safe if I, myself wasn’t permitted into her home for breastfeeding support because it was “too risky?” If I was not permitted to go into a home in order to weigh and assess a newborn baby, why should a mother not be concerned about taking him to the clinic for his vaccines? It felt completely disingenuous and I started to experience deep moral distress.

Every time I asked what the goal was to return to visiting families in their homes, I was given the same answer: “Let me check into it.” Who had decided to stop in-person nursing services? I couldn’t always tell because no one seemed to want to take that responsibility. The State Health department had told us to do what we were comfortable with as an agency. Sometimes I was told it was the safety and compliance officer, sometimes it was the director of public health.

Many of the nurses themselves did not want to return in person — which I understood. For the first time in my career, I didn’t have to worry about childcare, rush hour, or getting up in time to take a shower before work. I didn’t have to sit in a cramped, hot, smelly apartment with someone’s boogery child crawling all over me. I was pregnant with my fourth child and far more comfortable staying home. But that convenience didn’t make up for the guilt I felt.

The families that were part of our program made it possible for people like me to stay home. They went to work in grocery stores, restaurants, packing school lunches, construction, and working as nursing assistants in long-term care.

Then the vaccines came. Many had already recovered from Covid and found it to be mild, myself included. They were wary of the vaccine or felt they didn’t need it because they had already had the illness. But Public Health insisted through a variety of coercive means, that in order for us to feel safe around these people, they must get vaccinated.

A few days after my baby was born, our agency received its first shipment of the long awaited mRNA vaccines. We were short-staffed, so I called my manager and let her know that I would be willing to return 1-2 days per week to give vaccines. I was determined to do my part in ending the pandemic in order to get back to normal for the families on my caseload (not to mention my own family). I recall telling people that they were 95% protected from ever getting Covid at all. It was a hopeful and exciting time that was extremely short-lived.

Within months, we had people asking us just to give them a filled out vaccine card so that they could enter lotteries and earn incentives from Krispy Kreme. One of our nurses had someone tell her he would give her his stimulus check if she would just fill out the card. Of course, we declined these requests and bribes. By April, we were told by the state health department that we could start opening a 10-dose vial for 1 person and waste the other 9 doses, something that was unconscionable just weeks prior.

Then things started to turn even more sinister.

One afternoon, a young man sat down at my vaccine station in an angry manner. I asked what was going on, he said, “I’m only here because my work is telling me I have to get this to keep my job.” I set down my alcohol swab and removed my gloves saying “I’m sorry sir, but I can’t give you this vaccine if you are being coerced.” (At that time, I understood this to be the policy of public health.) He looked surprised. I told him that he appeared capable of making his own medical decisions and I could not take part in coercion. He and I chatted for a while about his personal risk factors for Covid, the known potential side effects of the vaccine, etc. In the end, he decided that he did want it after all, so I put my gloves back on and gave it to him. But the incident haunted me.

After that, I tried to avoid working at Covid vaccine clinics. But there was one that I ended up working at in September at a local community college. While sitting there with nearly no one showing up, I recounted this story to the nurse I was with to see what she thought about it. “We are at the point where people need to be forced,” was her reply. My heart sank. I never wanted to be part of forcing medical treatments on anyone.

Tears streamed down my cheeks as I turned in my resignation letter in November 2021. It had been an honor to be invited to do the work that I did, but I felt that I no longer belonged nor was welcome in my workplace. As I cleared out my desk, I came across infographics on the importance of babies seeing faces, the dangers of too much screen time, and notes from trainings that described the detrimental effects of social isolation. These were relics of a time when the well-being of children was the singular focus of my work, but that era in public health seemed to have passed.
 

Heliobas Disciple

TB Fanatic
https://www.msn.com/en-us/health/medical/lower-omicron-efficacy-led-to-fda-delay-on-pfizer-shot-in-young-kids/ar-AAU2a6Q
(fair use applies)

Lower Omicron Efficacy Led to FDA Delay on Pfizer Shot in Young Kids
Jared S. Hopkins, Stephanie Armour
11 hrs ago

U.S. health regulators delayed their review of Pfizer Inc.’s Covid-19 vaccine in children under 5 years old because the initial two-dose series so far wasn’t working well against the Omicron variant during testing, people familiar with the decision said.

An early look at data showed the vaccine to be effective against the Delta variant during testing while that was the dominant strain, but some vaccinated children developed Covid-19 after Omicron emerged, the people said.

So few study subjects, whether vaccinated or unvaccinated, developed Covid-19 during testing thus far that the small number of Omicron cases made the vaccine appear less effective in an early statistical analysis, the people said.

As more cases emerge, Pfizer’s shot might wind up providing stronger protection against Omicron, the people said, if the bulk of infections are in unvaccinated subjects.

Officials from the Food and Drug Administration and Pfizer agreed it would be better to wait for the additional cases, the people said. The extra time would let the agency assess the vaccine’s effectiveness as either two doses or three, they said. The FDA was going to make its decision by looking at whether the shot generated immune responses comparable with those seen in older people.

The delay will also allow regulators to see how a third dose performs, the people said. That additional dose is given at least two months after the second shot. The FDA hopes to have a decision on the vaccine this spring, the people said; Pfizer has said it expects study results in early April.

Yet researchers are counting on more cases just as the Omicron wave declines in many countries. That could make it difficult to get enough Covid-19 cases to determine efficacy quickly, potentially forcing researchers to rely on immune responses.

The decision to wait, which came days before the FDA was expected to issue its determination, angered some parents who were eager to vaccinate their young children and confused others unsure of what to do. It also prompted some health experts to criticize the FDA, saying it should have waited all along to avoid authorizing a medicine that didn’t generate a strong enough immune response.

The FDA had urged Pfizer to apply for authorization in children ages 6 months to 5 years old, though the company had been planning to wait for testing to finish.

The vaccine, from Pfizer and partner BioNTech SE, is in wide use among people 5 years and older. Younger children are the only group waiting for FDA clearance, and Pfizer has been testing a lower dose of its vaccine in that cohort.

The testing was taking two forms: For a faster assessment, the companies explored whether the shot produced the same level of immune response in the younger children as it did in older people. They were also looking to see how many young study subjects developed Covid-19, then analyzing the numbers of vaccinated and unvaccinated people who develop cases to determine the shot’s efficacy.

In a preliminary look at the data, researchers saw the vaccine was about 50% effective in the children when Delta was the predominant strain circulating, despite mixed results in whether the vaccine generated the desired immune response, the people said.

In children ages 6 months to 2 years, the shot generated an immune response comparable to that seen in young adults, but it didn’t do so in children ages 2 to 4 years, according to the companies. Independent vaccine experts say they don’t know why the vaccine performed poorly in some children, and the companies have declined to speculate.

One factor, the experts say, could be that children have less developed immune systems. The relatively small number of Covid-19 cases that have emerged in study subjects could also potentially skew results.

Some health experts point to the low dosage given to the young children as another possible factor. Pfizer and BioNTech are testing a 3-microgram dose in children under 5 years, one-tenth the dose given to older children and adults. Using a higher dose risked more adverse effects such as sore arms and fever, one of the people familiar with the vaccine’s development said.

Pfizer had studied a higher dose of 10 micrograms in a small group of children in an early study last year, but the drugmaker said it found too many of the subjects experienced side effects such as fevers and chills.

Testing has found the 3-microgram doses have a good safety profile, Pfizer has said. The companies have said they hadn’t observed any serious safety concerns during the testing.

The continuing study is evaluating a third dose at the same 3-microgram dose. The extra shot has produced a strong immune response in testing, one of the people said.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

EXC: Wuhan’s ‘Batwoman’ Advises a U.S. Taxpayer-Funded Group Which Lobbies Congress for Lower Standards for Foreign BioLabs.
The long-time Daszak collaborator has more influence on America's scientific community than many realize.
by Natalie Winters
February 18, 2022

Dr. Shi Zhengli – the notorious Wuhan Institute of Virology’s coronavirus researcher – was elected to a leadership role for the American Academy of Microbiology, which receives millions of dollars from U.S. taxpayers. The Academy has also advised the federal government to “remove hurdles for international collaboration” in high-level biosafety labs, The National Pulse can reveal.

Also known as Wuhan’s “Batwoman,” Dr. Shi runs the controversial Chinese laboratory’s Center for Emerging Infectious Diseases and has received grants from Anthony Fauci’s National Institue of Health (NIH) agency to manipulate bat coronaviruses to become deadlier to humans. To many, this is where COVID-19 began.

Now, The National Pulse can reveal that despite being a “longtime collaborator” of EcoHealth Alliance President Peter Daszak, and becoming instrumental in the cover-up of COVID-19’s origins, Shi has a leadership position in the American scientific establishment at cost to the U.S. tax payer.

Dr. Shi was elected to serve as a fellow in the American Academy of Microbiology (AAM) – the American Society of Microbiology’s (ASM) “honorific leadership group” – in January 2019.

She still retains a biography page on the ASM website, which suggests the fellowship is still active. Despite several requests for comments from The National Pulse, neither the ASM nor the AAM responded to inquiries about Shi’s current status or details surrounding her fellowship.

Get On Gettr
Screen-Shot-2022-02-01-at-7.23.08-PM-800x362.png

Shi’s active bio on the ASM website.

Shi’s advisory role within the ASM gives her influence over the direction of the body, which received over $5.3 million in federal funds in 2020.

ASM has an advocacy program where it deploys its members to lobby Congress on public health issues and research regulations, including policies relevant to Biosafety Level 4 (BSL-4) facilities. The Wuhan Institute of Virology hosts a BSL-4 laboratory.
COVID Positive? In South Korea, You Might Be Barred From Voting.
Professor Ronald Atlas testified before Congress on behalf of the ASM in 2009, revealing the group had been advising the federal government on high-containment laboratories.

“During the past 2 years, the ASM has met with the Trans- Federal Task Force on Biosafety and Biocontainment Oversight and the Executive Order Working Group on strengthening the biosecurity of the United States and made a number of recommendations to those groups…” – Prof. Atlas

“These are not weapons laboratories; rather, they are research laboratories where investigations are carried out with the aim of protecting public health,” Atlas added.

On behalf of the ASM, Atlas also recommends that the NIH should change its regulation of international collaboration in these high-risk facilities:

“The NIH requirements that foreign institutions must have comparable facilities and standards that are U.S. Collaborative should be changed to remove hurdles for international collaboration.”

Daszak – a long-time friend and collaborate of Shi – was removed from the COVID-19 origins investigative team after exclusive National Pulse reporting into his unprecedented conflicts of interest.

.
 

Heliobas Disciple

TB Fanatic
(fair use applies)




Data suggests pandemic fatalities much higher than estimated
February 18, 2022
by Dartmouth College


1645262260704.jpeg
FIG. 1. Percentages of adults reporting daily death in household, expected percentage in 2020, and daily confirmed COVID deaths in India, 1 June 2020 to 1 July 2021.COVID Tracker deaths (red line, left vertical scale) represent COVID deaths reported daily (smoothed for rolling 7-day averages) at age 35 or older, less a subtraction value of 0.59% to represent nonhousehold reporting. Expected all-cause deaths (gray dashed line, left vertical scale) per year of 3.4% (see text), with 7-day smoothed weekly adjustment from variation observed among 480,000 deaths in the Million Death Study from 2004 to 2014. Confirmed COVID deaths (blue bars, right vertical scale) are daily reports from Covid19india.org (2). Credit: DOI: 10.1126/science.abm5154

When a COVID-19 wave hit India over the winter and spring of 2021, hospitals were filled beyond capacity, oxygen was nearly impossible to obtain, and community networks for tending to the dead were overwhelmed. Government reporting at the time put the death toll at under a million.

A more accurate measure of COVID-19 deaths in India puts that number at 3.2 million people, according to a paper co-authored by Associate Professor of Economics Paul Novosad and an international team of researchers.

"The analyses find that India's cumulative COVID deaths by September 2021 were six to seven times higher than reported officially," the researchers wrote in the paper published last month in Science.

"You have to put that into context," says Novosad. "At the time that we were writing this, India was reporting about half a million official COVID deaths, the World Health Organization was reporting about 4 to 5 million COVID deaths globally, so just this adjustment—just correctly counting the deaths in India—is going to raise the global mortality count of COVID by almost 50%."

The team reviewed data on all causes of death from an independent survey of 140,000 adults, and from two government data sources including deaths reported in health facilities and registered deaths in 10 states in India. They compared these counts to the patterns found in previous years without COVID and found that total deaths increased by 26% to 29% in the COVID period compared to total deaths in past years. This range was consistent across separate data sources, the researchers wrote.

"We're triangulating on this number from a lot of different directions and have broad agreement regarding the range that we're finding," Novosad says.

Novosad's work uses many new kinds of data, including measures of well-being generated from satellite images, data collected by government programs, and archival administrative records not previously used for policy design. His research lab, which focuses on India, has created an open source data platform to support socioeconomic research in India and the developing world.

"A large part of my research agenda is based on finding new, 21st-century data sources and mobilizing them for better research and policy," he says.

The global pandemic presented many critical questions about how governments and organizations can respond that Novosad believes this work can help answer.

"The decisions you make are better if they're based on true facts about the world. If you don't have data, then you just have to work on stories and impressions," he says. "We need an empirical foundation for this kind of work."
.
 

Heliobas Disciple

TB Fanatic
(fair use applies)




Review highlights impact of long COVID on cardiovascular system
by University of Oxford
February 18, 2022

The wide-ranging effects of long COVID and the associated issues for healthcare providers have be en revealed in a new review of the major studies into the condition, which specifically highlights the impact of Long COVID impact on the cardiovascular system.

The review, published in the European Heart Journal, was conducted by researchers from the University of Oxford, the University of Wisconsin School of Medicine and Public Health, Royal Brompton Hospital and Imperial College, London, and the University of Zurich, Switzerland.

The review spans each step from a patient's original coronavirus infection and the direct impacts, such as myocardial infarction or inflammatory myocarditis, to the long-term impacts on aspects of wellbeing such as mental health and fatigue.

The researchers also concluded that current evidence for the treatment of long COVID is lacking and that our current understanding of pathophysiological mechanisms and treatment options remains limited. They also found that the vast inequalities in healthcare provision exposed by COVID-19 continue to be magnified by long COVID, a problem that calls for global humanitarian efforts to promote and fund equitable access to healthcare, social and welfare support, and vaccines across the world.

Dr Betty Raman, of Oxford's Radcliffe Department of Medicine, said that "long COVID is emerging as a major public health issue, which makes it important that we better understand the long-term effects of COVID-19 to improve our treatment of it."

"This review highlights the wide range of short and long-term health impacts and the mechanisms behind them, which is key to providing treatment and ongoing care."

Professor Stefan Neubauer, Head of the Division of Cardiovascular Medicine, Radcliffe Department of Medicine, said that "long COVID is a huge medical challenge. This review gives a comprehensive update on its effect on the cardiovascular system, and will also be important in guiding future research into the condition and for finding new treatments."

Dr Betty Raman is leading one of the first randomized, double-blind, placebo-controlled studies in the UK. Other trials to date have been open label or non-random assignment of therapy. The team's work is supported by the NIHR Oxford Biomedical Research Centre, a partnership between Oxford University Hospitals NHS Foundation Trust and the University of Oxford.

Professor Thomas Lüscher, Director of Research, Education and Development, Royal Brompton and Harefield Clinical Group, said that "this is the first review that summarizes the diverse evidence on Long Covid and provides a balanced picture of this important issue. The pandemic brought not only acute illness and death, it became a chronic disease of many organs, not just the lungs, but the heart, brain, kidney among others."

"Long Covid is, besides its huge impact for the affected individual, of great societal and economic importance as it leads to leave of absence from work, reduced work performance and hence unforeseen costs."
.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

Federal Appeals Court: United Airlines Vaccine Mandate ‘Coerced’ Employees to ‘Violate Religious Convictions’
Katherine Hamilton
18 Feb 2022

A federal appeals court on Thursday ordered further review of United Airlines’ coronavirus vaccine mandate, calling it “coercive” and reversing a lower court ruling.


A three-judge panel in the U.S. Court of Appeals for the Fifth Circuit ruled 2-1 to return the issue to District Judge Mark Pittman, who previously rejected employees’ request for a preliminary junction. In his opinion, Pittman was sympathetic to employees but said he was bound by court precedent, and he declined the request because employees could not prove “irreparable harm,” one of four variables which need to be satisfied in court in order for a judge to issue an injunction and preserve the “status quo” during litigation. Federal Judges Andy Oldham and Jennifer Elrod reversed Pittman’s ruling, pointing to the “rather unique” nature of the case.


“Plaintiffs allege a harm that is ongoing and cannot be remedied later: they are actively being coerced to violate their religious convictions. Because that harm is irreparable, we reverse the district court,” Oldham, a President Donald Trump appointee, and Elrod, a George W. Bush appointee, wrote in their opinion.


The panel heard arguments in the case in early January. The Fifth Circuit, which is widely considered the most conservative appeals court, initially rejected an emergency request to halt the mandate in mid-December, but granted a motion to expedite an appeal in the case after Pittman’s decision to refuse the injunction in November 2021.


United Airlines is estimated to have placed around 2,000 employees who were granted religious or medical exemptions on unpaid leave for foregoing vaccination — a measure the company argued is a reasonable accommodation to its policy. Those employees have also been stripped of their health benefits and many are the subject of a non-compete clause. The lawsuit, which was originally filed by six United Airlines employees in September of 2021, alleges that the company violated Title VII of the Civil Rights Act of 1964 and the Americans with Disabilities Act (ADA) by discriminating against them based on their religious beliefs and medical conditions.


Despite being “disturbed” by United Airlines’ “seemingly calloused approach to its employees’ deeply personal concerns,” Pittman, at the time, specifically said a loss of income does not constitute irreparable harm.


“The Court is not insensitive to Plaintiffs’ plight. A loss of income, even temporary, can quickly ripple out to touch nearly every aspect of peoples’ lives, and the lives of their families and dependents. But the Court’s analysis must be guided by the law, not by its sympathy,” Pittman said in his opinion, acknowledging that some plaintiff’s in the lawsuit will suffer hardships such as losing income to pay for cancer treatments, becoming homeless, and being unable to pay for their child’s’ education.


In response, Oldham and Elrod distinguished two separate aspects of irreparable harm in the United case, which informed their decision to reverse Pittman’s ruling.


“The first is United’s decision to place them on indefinite unpaid leave; that harm, and any harm that flows from it, can be remedied through backpay, reinstatement, or otherwise,” the judges wrote. “The second form of harm flows from United’s decision to coerce the plaintiffs into violating their religious convictions; that harm and that harm alone is irreparable and supports a preliminary injunction.”


Ronald Reagan appointee Jerry Smith penned the dissent, accusing his colleagues of “play[ing] CEO of a multinational corporation.”


“…The majority shatter every dish in the china shop. It rewrites Title VII to create a new cause of action,” Smith said.


Smith argued that the panel should have affirmed Pittman’s order denying the injunction.


“For every conceivable reason that the plaintiffs could lose this appeal, they should,” he said.


The Fifth Circuit judges ordered the case to go back to Pittman for review. With Pittman’s concerns about irreparable harm assuaged, he will consider remaining preliminary injunction factors and ultimately decide whether unvaccinated employees with exemptions will return to work.


In November, Pittman notably told United Airlines employees that besides their inability to prove irreparable harm, their “arguments appear compelling and convincing at this stage.”


“United’s mandate thus reflects an apathy, if not antipathy, for many of its employees’ concerns and a dearth of toleration for those expressing diversity of thought,” he wrote in part.


The case is Sambrano v. United Airlines, No. 21-11159 in the U.S. Court of Appeals for the Fifth Circuit.
 

Heliobas Disciple

TB Fanatic
(fair use applies)


Bill Gates: The Omicron Variant Has Delivered More Immunity Around The World Than We Have Done With Vaccines
Posted By Tim Hains
February 18, 2022

Microsoft founder Bill Gates reflected on Covid-19 and discussed how the world should prepare for the next pandemic on a panel Friday at the Munich Security Conference.

BILL GATES: Sadly, the virus itself, particularly the variant called Omicron, is a type of vaccine. That is it creates both B cell and T cell immunity. And it has done a better job of getting out to the world population than we have with vaccines.

If you do surveys of African countries, something like 80% of people have been exposed either to the vaccine or to various variants. What that does is it means the chance of severe disease, which is mainly related to being elderly and having obesity or diabetes, those risks are now dramatically reduced because of that infection exposure.

It's sad, we didn't do a great job on therapeutics. Only here, two years in, do we have a good therapeutic. Vaccines took us two years to get to oversupply. Today there are more vaccines than there are demand for vaccines. And that wasn't true. And next time we should try and make it instead of two years, we should try and make it like six months.

Certainly, some of the standardized platforms, including mRNA, would allow us to do that. It took us a lot longer this time than it should have...

QUESTION: Are we going to see another pandemic before we are able to beat this one?

BILL GATES: We'll have another pandemic. It will be a different pathogen next time.

We'll have some rebound. This pathogen we don't have a tool to do eradication. We'd like to have a new generation of vaccines that would be suitable. Ideally, we'd get rid of families of respiratory viruses including the flu family and the coronavirus family.

And I do think in the next decade we can come up with an eradication vaccine. That's an aspiration, not a guarantee, but we should be putting R&D dollars in that.

There's already a lot of work that has been done on a universal flu vaccine and the data on that looks very promising.

So we'll have rebounds, but they'll be more typical seasonal flu levels, where of course we don't generally shut things down. Although in the future, some degree of mask-wearing probably will be indicated. But we won't get death levels at the kind of acute level we're kind of experiencing today as the Omicron wave passes through on a global basis.

View: https://youtu.be/U70Q9WqbMFM?t=405

Munich Security Conference: Finding a way out of the pandemic
Streamed live 16 hours ago
1hr 6 min
VIDEO IS PROMPTED TO START AT 6:45 MINUTE POINT FOR THIS PART OF THE CONVERSATION
 

Heliobas Disciple

TB Fanatic
(fair use applies)

Bill Gates says Covid risks have 'dramatically reduced' but another pandemic is coming
Published Fri, Feb 18 20221:40 PM EST
Karen Gilchrist

Key Points
  • Bill Gates told CNBC Friday that the risks of severe disease from Covid-19 have "dramatically reduced" but another pandemic is all but certain.
  • Speaking at Germany's annual Munich Security Conference, Gates said that a potential new pandemic would likely stem from a different pathogen.
  • Advances in medical technology could cut vaccine production times to six months, Gates added.

Bill Gates said Friday that the risks of severe disease from Covid-19 have "dramatically reduced" but another pandemic is all but certain.

Speaking to CNBC's Hadley Gamble at Germany's annual Munich Security Conference, Gates, co-chair of the Bill & Melinda Gates Foundation, said that a potential new pandemic would likely stem from a different pathogen to that of the coronavirus family.

But he added that advances in medical technology should help the world do a better job of fighting it — if investments are made now.

"We'll have another pandemic. It will be a different pathogen next time," Gates said.

Two years into the coronavirus pandemic, Gates said the worst effects have faded as huge swathes of the global population have gained some level of immunity. Its severity has also waned with the latest omicron variant.

However, Gates said that in many places that was due to virus itself, which creates a level of immunity, and has "done a better job of getting out to the world population than we have with vaccines."

"The chance of severe disease, which is mainly associated with being elderly and having obesity or diabetes, those risks are now dramatically reduced because of that infection exposure," he said.

Gates said it was already "too late" to reach the World Health Organization's goal to vaccinate 70% of the global population by mid-2022. Currently 61.9% of the world population has received at least one dose of a Covid-19 vaccine.

He added that the world should move faster in the future to develop and distribute vaccines, calling on governments to invest now.

"Next time we should try and make it, instead of two years, we should make it more like six months," Gates said, adding that standardized platforms, including messenger RNA (mRNA) technology, would make that possible.

"The cost of being ready for the next pandemic is not that large. It's not like climate change. If we're rational, yes, the next time we'll catch it early."

Gates, through the Bill & Melinda Gates Foundation, has partnered with the U.K.'s Wellcome Trust to donate $300 million to the Coalition for Epidemic Preparedness Innovations, which helped form the Covax program to deliver vaccines to low- and middle-income countries.

The CEPI is aiming to raise $3.5 billion in an effort cut the time required to develop a new vaccine to just 100 days.
 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=lAiXeDfrRjk


JAMA: mRNA vaccines elevate myocarditis risk by 133x
38 min 11 sec
Premiered 9 hours ago
Peak Prosperity

This program is dedicated to the memory of Brandon Watt of Ontario Canada, his wife and children.
A new study out on Jan 25th in JAMA shows that the mRNA vaccines elevate the risk of myocarditis by 133x above background rates. JAMA Report: https://jamanetwork.com/journals/jama... This is particularly true for men/boys, with a median age of just 21 years. This study almost certainly is an undercount of the true risk elevation. The VAERS data is notorious for being a fraction of the true rate of adverse event incidence. This has been true every single time a study in VAERS is conducted. You’d think the CDC would be at least somewhat interested in how badly this system operates, but you’d be wrong. They are, instead, more concerned with burying the data rather than surfacing better data and then studying it.
Link: Israeli Newspaper on Study https://www.israelnationalnews.com/ne...
 

Heliobas Disciple

TB Fanatic
View: https://www.youtube.com/watch?v=NVXA9posslo


Please send to politicians
18min 36sec
Feb 19, 2022

Dr. John Campbell

Germany’s vaccination board STIKO ständige Impfkomission, Standing commission for vaccination https://www.rki.de/DE/Content/Infekt/... Now recommends aspiration The vaccine is to be injected only intramuscular (i.m.), and in no case intradermal, subcutaneous, or intravenous. In animal models, direct intravenous injection of an mRNA vaccine has led to Myopericarditis (both clinically and histopathologically). Although inadvertent intravenous injections are rare during application of intramuscular vaccines, aspiration of the needle is a sensible precaution when vaccinating against COVID-19 and can lead to increased safety. Ferdinand, thank you Denmark https://en.ssi.dk/news/epi-news/2021/... Basically, we need to change the vaccine administration guidelines to include precautionary aspiration, prior to pushing in the vaccine. This will prevent cases of inadvertent intravascular administration of vaccine. Here is some discussion to suggest inadvertent intravascular vaccine administration is a variable in the aetiology of complications after adenoviral vector vaccine administration and after mRNA vaccines. These adverse events, although rare have reduced public confidence in covid vaccination, especially amongst the young, where vaccine rates are lowest. It has long been known that intravenous injection of adenovirus leads to TTS in mice https://ashpublications.org/blood/art... Now, new covid vaccine specific work agrees with this previous work Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration (29th June 2021) https://www.biorxiv.org/content/10.11... The authors conclude, ‘Our work contributes to the understanding of TTS and highlights accidental intravenous injection as potential mechanism for post-vaccination TTS.’ ‘We show that intravenous but not intramuscular injection of ChAdOx1 triggers platelet-adenovirus aggregate formation and platelet activation.’ ‘Hence, safe intramuscular injection, with aspiration prior to injection, could be a potential preventive measure when administering adenovirus-based vaccines.’ Also after giving mRNA vaccines A new study finds that giving mice intravenous mRNA vaccine also causes heart inflammation in mice. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model (August 2021) https://academic.oup.com/cid/advance-... ‘Our study indicates that IV injection of vaccines might partially contribute to this clinical phenotype, thus warranting a reconsideration of the practice of IM injection without aspiration, which carries the risk of inadvertent IV injection.’ Agreement from ‘fact check’ from Leo Nicolai, Cardiology Fellow, Ludwig Maximilian University of Munich: (German Centre for Cardiovascular Research) https://healthfeedback.org/claimrevie... ‘Indeed, there is peer-reviewed work showing in mice that possibly intravenous injection of mRNA vaccine leads to myocardial inflammation.’ ‘that intravenous injection of adenoviral vector based vaccine (AZ1222, ChAdOx1) leads to thrombocytopenia and platelet-directed immune responses, offering a possible explanation for vaccine-induced thrombosis/thrombocytopenia’ ‘these data might indicate a simple measure to lower the incidence of vaccine-induced side effects,’ ‘There is a lack of data on frequency and effects of IV injection in humans.’ Denmark has changed their national guidelines https://en.ssi.dk/news/epi-news/2021/... Based on a precautionary principle, we recommend aspiration before injection. https://www.youtube.com/watch?v=H7ina... Evidence from Dr. Peter Gaillard (microparticulate pharmacologist) https://www.linkedin.com/pulse/astraz... Case study evidence Metallic taste in the mouth seconds after ‘intramuscular’ mRNA vaccine administration, (in the absence of an allergic reaction)
 

Heliobas Disciple

TB Fanatic
(fair use applies)


COVID-19 survivors face increased mental health risks up to a year later
by Kristina Sauerwein, Washington University School of Medicine in St. Louis
February 19, 2022

As the COVID-19 pandemic stretches into its third year, countless people have experienced varying degrees of uncertainty, isolation and mental health challenges.

However, those who have had COVID-19 have a significantly higher chance of experiencing mental health problems, according to researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care System. Such disorders include anxiety, depression, and suicide ideation, as well as opioid use disorder, illicit drug and alcohol use disorders, and disturbances in sleep and cognition.

In a large, comprehensive study of mental health outcomes in people with SARS-CoV-2 infections, researchers found that such disorders arose within a year after recovery from the virus in people who had serious as well as mild infections.

Overall, the study found that people who had COVID-19 were 60% more likely to suffer from mental health problems than those who were not infected, leading to an increased use of prescription medication to treat such problems and increased risks of substance use disorders including opioids and nonopioids such as alcohol and illicit drugs.

The findings are published Feb. 16 in the journal The BMJ.

"We know from previous studies and personal experiences that the immense challenges of the past two years of the pandemic have had a profound effect on our collective mental health," said senior author Ziyad Al-Aly, MD, a clinical epidemiologist at Washington University. "But while we've all suffered during the pandemic, people who have had COVID-19 fare far worse mentally. We need to acknowledge this reality and address these conditions now before they balloon into a much larger mental health crisis."

More than 403 million people globally and 77 million in the U.S. have been infected with the virus since the pandemic started.

"To put this in perspective, COVID-19 infections likely have contributed to more than 14.8 million new cases of mental health disorders worldwide and 2.8 million in the U.S.," Al-Aly said, referring to data from the study. "Our calculations do not account for the untold number of people, likely in the millions, who suffer in silence due to mental health stigma or a lack of resources or support. Further, we expect the problem to grow because cases seem to be increasing over time. Frankly, the scope of this mental health crisis is jarring, frightful and sad.

"Our goal was to provide a comprehensive analysis that will help improve our understanding of the long-term risk of mental health disorders in people with COVID-19 and guide their post-infection health care," added Al-Aly, who treats patients within the VA St. Louis Health Care System. "To date, studies on COVID-19 and mental health have been limited by a maximum of six months of follow-up data and by a narrow selection of mental health outcomes—for example, examining depression and anxiety but not substance use disorders."

The researchers analyzed de-identified medical records in a database maintained by the U.S. Department of Veterans Affairs, the nation's largest integrated health-care delivery system. The researchers created a controlled dataset that included health information of 153,848 adults who had tested positive for COVID-19 sometime from March 1, 2020, through Jan. 15, 2021, and who had survived the first 30 days of the disease. Few people in the study were vaccinated prior to developing COVID-19, as vaccines were not yet widely available at the time of enrollment.

Statistical modeling was used to compare mental health outcomes in the COVID-19 dataset with two other groups of people not infected with the virus: a control group of more than 5.6 million patients who did not have COVID-19 during the same time frame; and a control group of more than 5.8 million people who were patients from March 2018 through January 2019, well before the pandemic began.

The majority of study participants were older white males. However, because of its large size, the study included more than 1.3 million females, more than 2.1 million Black participants, and large numbers of people of various ages.

Compared with those in the control groups without any infections, people who contracted COVID-19 were 35% more likely to suffer from anxiety disorders and nearly 40% more likely to experience depression or stress-related disorders that can affect behavior and emotions. This coincided with a 55% increase in the use of antidepressants and a 65% growth in the use of benzodiazepines to treat anxiety.

Similarly, people who had recovered from COVID-19 were 41% more likely to have sleep disorders and 80% more likely to experience neurocognitive decline. The latter refers to forgetfulness, confusion, a lack of focus, and other impairments commonly known together as brain fog.

More worrisome, compared with people without COVID-19, those infected with the virus were 34% more likely to develop opioid use disorders and 20% more likely to develop nonopioid substance use disorders involving alcohol or illegal drugs. They were also 46% more likely to have suicidal thoughts.

"People need to know that if they have had COVID-19 and are struggling mentally, they're not alone, and they should seek help immediately and without shame," Al-Aly said. "It's critical that we recognize this now, diagnose it and address it before the opioid crisis snowballs and we start losing more people to suicide.

"There needs to be greater recognition of these issues by governments, public and private health insurance providers, and health systems to ensure that we offer people equitable access to resources for diagnosis and treatment," he added.

To better understand whether the increased risk of mental health disorders is specific to SARS-CoV-2 virus, the researchers also compared the COVID-19 patients with 72,207 flu patients, including 11,924 who were hospitalized, from October 2017 through February 2020. Again, the risk was significantly higher—27% and 45%—in those who had mild and serious COVID-19 infections, respectively.

"My hope is that this dispels the notion that COVID-19 is like the flu," Al-Aly said. "It's so much more serious."

Because hospital stays can precipitate anxiety, depression and other mental conditions, the researchers compared people who were hospitalized for COVID-19 during the first 30 days of the infection to those hospitalized for any other cause. Mental health disorders were 86% more likely in people hospitalized for COVID-19.

"Our findings suggest a specific link between SARS-Co-V-2 and mental health disorders," Al-Aly continued. "We're not certain why this is, but one of the leading hypotheses is that the virus can enter the brain and disturb cellular and neuron pathways, leading to mental health disorders.

"What I'm absolutely certain about is that urgent attention is needed to identify and treat COVID-19 survivors with mental health disorders," he said.
 

Heliobas Disciple

TB Fanatic
(fair use applies)



Gut health compromised in severe COVID-19
by King's College London
February 18, 2022

New research of samples of intestine from people who have died of COVID-19 has shown the impact of the virus on the gut immune system.


The study is published today in Frontiers in Immunology by researchers from King's College London with funding by the Medica Research Council via the UK Coronavirus Immunology Consortium, and support from the NIHR Guy's and St Thomas' BRC. It looked at samples of gastrointestinal tract from patients who died after being diagnosed with COVID-19 during the first wave of the pandemic.


Lymphoid tissue in the gut normally maintains healthy intestinal microbial populations which are essential for good health. Researchers observed that the system that would normally regulate the composition of the microbial communities—otherwise known as Peyer's Patches—were severely disrupted in severe COVID-19. This was irrespective of whether there was evidence of virus present in the gut or not.


While severe COVID-19 can lead to breathing problems and high fever, some patients can experience diarrhea, nausea and vomiting, which suggests involvement of the gastrointestinal tract.


Professor Jo Spencer, from King's College London said that "this study shows that in severe COVID-19, this key component of the immune system is disrupted, whether the intestine itself is infected with SARS-CoV-2 or not. This would likely contribute to the disturbances in intestinal microbial populations in COVID-19 reported by others."


Observations of the samples found the structure and cellularity in Peyer's Patches—a grouping of lymphoid follicles that lines the small intestines—had been altered independent of the local levels of the virus. This included depletion of the germinal centers, which normally propagate antibody producing cells, in patients who died with COVID-19.


This resulting poor local immunity could lead to a reduction in microbial diversity, known as dysbiosis. Researchers also noted that the findings suggest that oral vaccination may not be effective if the patient is already ill, as the gut immune system is already compromised.


Professor Spencer added that "in the future it will be important to understand factors driving such lymphoid tissue dysregulation in severe inflammatory responses."
 

Heliobas Disciple

TB Fanatic
(fair use applies)

“Everyone is at Risk for Blood Clots!” – CDC and Pfizer Issue Urgent Warnings on Blood Clots Even in “The Healthiest Athletes”
By Jim Hoft
Published February 19, 2022 at 7:45am

Screen-Shot-2022-02-18-at-10.21.26-PM.jpg


Both CDC and Pfizer have recently issued a public warning about “blood clots.”

Last February 10, the CDC issued a warning normalizing the idea that young adults and healthy athletes develop blood clots.

Of course, no one has ever heard of this frequent phenomenon before the COVID vaccines.

“#DYK [do you know] that anyone can develop a blood clot? Whether you’re an athlete or a fan, don’t let a blood clot ruin the big game this weekend. Learn how to protect your health: https://bit.ly/2lOpGEB,” CDC tweeted out.

#DYK that anyone can develop a blood clot? Whether you’re an athlete or a fan, don’t let a blood clot ruin the big game this weekend. Learn how to protect your health: What is Venous Thromboembolism? | CDC.
— CDC (@CDCgov) February 10, 2022


The CDC failed to mention on their website the COVID-19 vaccines as one of the factors that can increase this risk.

Screen-Shot-2022-02-18-at-10.02.17-PM.jpg


Last year, a stunning new study that was conducted by researchers from the Mayo Clinic in Rochester, Minnesota, and published in the Journal of the American Medical Association (JAMA), has concluded that the Johnson & Johnson Covid vaccine increases the risk of developing a rare and deadly blood clotting condition in the brain.

A study by Oxford University early last year also revealed that the number of people who developed blood clots after getting vaccinated was about the same for those who get Pfizer and Moderna vaccines as they are for the AstraZeneca, Market Watch reported.

Following CDC’s caution, Pfizer has issued a public warning about “deep vein thrombosis” or blood clots in the vein on February 14.

“Deep vein thrombosis (#DVT), a blood clot in a deep vein, can travel to the lungs, leading to a pulmonary embolism (#PE). Symptoms of PE include difficulty breathing and chest pain. Contact your doctor if experiencing symptoms—this is no time to wait,” Pfizer tweeted out.

Deep vein thrombosis (#DVT), a blood clot in a deep vein, can travel to the lungs, leading to a pulmonary embolism (#PE). Symptoms of PE include difficulty breathing and chest pain. Contact your doctor if experiencing symptoms—this is no time to wait.
— Pfizer Inc. (@pfizer) February 14, 2022


.

 

Heliobas Disciple

TB Fanatic
(fair use applies)

Creepy Bill Gates Says Misinformation Enhanced Vaccine Hesitation and Led to Deaths – Claims Wearing Masks Is Like Wearing Pants
By Joe Hoft
Published February 19, 2022 at 11:30am

Bill-Gates-3.jpg


In a panel discussion in Munich this week, Bill Gates claimed media reporting other than Mainstream Media reporting led to COVID deaths while comparing wearing masks to wearing pants.

The Daily Caller reported on comments made by Gates this week.

While speaking on a COVID-19 panel at the Munich Security Conference, Gates referred to the amount of “misinformation” surrounding his role in the handling of the virus to be “wild,” before appearing to mock critics of himself, Dr. Anthony Fauci and other public health figures. “You almost have to laugh about it. I mean, you know, Dr. Fauci and I are just killing millions of people to make money,” Gates quipped. “You know, hydroxychloroquine’s this miracle cure that … he and I have masterminded, avoiding people saving their lives by taking this thing."
Gates added, “there’s no doubt that the misinformation, enhanced vaccine hesitancy and that maps to hundreds of 1000s of deaths. There’s no doubt that the idea that, you know, we need the freedom not to wear a mask, you know, and that that’s some, you know, thing that you’ve got to show that in many cases that led to spreading the disease into locations where elderly people had very high death rates.”
Gates appeared to scoff at the arguments made by politicians and individuals opposed to mask mandates, before jokingly comparing grievances against compulsory masking to those against wearing pants in public.

Gates’s comments were caught on tape and shared in social media.

Bill Gates tells CNBC’s @_HadleyGamble there is “no doubt” misinformation enhanced vaccine hesitation, and led to deaths pic.twitter.com/TuHZ9FH0NO
— Emma Graham (@themmagraham) February 18, 2022

We’ve reported on other things “expert on vaccines” Bill Gates shared these past few years like admitting that the vaccines didn’t work in stopping the transmission of COVID.

.
 

Heliobas Disciple

TB Fanatic
(fair use applies)

Biden quietly sent a letter to corrupt Speaker Pelosi and the US House and Senate stating that he is extending the National Emergency related to COVID beyond the current termination date of March 1st with no end date provided.

The man-made crisis continues.

Old senile Joe Biden sent a letter to Speaker Pelosi noting that he is extending the National Emergency related to COVID well beyond its current termination date set for March.

The Conservative Treehouse reports:

Joe Biden informed Speaker of the House Nancy Pelosi that he intends to extend the federal National Emergency declaration beyond its termination date in March. [STATUTE HERE]
By statute the State of a National Emergency expires one year after initial declaration. That meant the COVID National Emergency declaration was scheduled to end March 1st. However, the statute allows the extension if the executive office informs the legislative branch within the 90-day window prior to expiration.
Biden informed Nancy Pelosi today of his intent to extend the National Emergency. Both the House and Senate will now have to schedule a vote to support the extension [SEE HERE]:

Here is Biden’s notice:

Section 202(d) of the National Emergencies Act (50 U.S.C. 1622(d)) provides for the automatic termination of a national emergency unless, within 90 days prior to the anniversary date of its declaration, the President publishes in the Federal Register and transmits to the Congress a notice stating that the emergency is to continue in effect beyond the anniversary date. In accordance with this provision, I have sent to the Federal Register for publication the enclosed notice stating that the national emergency declared in Proclamation 9994 of March 13, 2020, beginning March 1, 2020, concerning the coronavirus disease 2019 (COVID-19) pandemic, is to continue in effect beyond March 1, 2022.
There remains a need to continue this national emergency. The COVID-19 pandemic continues to cause significant risk to the public health and safety of the Nation. More than 900,000 people in this Nation have perished from the disease, and it is essential to continue to combat and respond to COVID-19 with the full capacity and capability of the Federal Government.
Therefore, I have determined that it is necessary to continue the national emergency declared in Proclamation 9994 concerning the COVID-19 pandemic.

Biden’s decision to keep the emergency going has no end date.
 

Heliobas Disciple

TB Fanatic
(fair use applies)



Early Outpatient Treatment for COVID-19: The Evidence
By Paul Elias Alexander
January 22, 2022

The evidence accumulated very early on in the pandemic that the use of sequenced multi-drug therapeutics (SMDT) under physician guidance was beneficial and that some medications were safe and effective. We refer to repurposed
therapeutics that have been regulatory approved and have been used in some instances for decades for other illnesses.

We have extensively written and published treatment algorithms and protocols as well as evidence of the benefit of early outpatient (ambulatory) treatment of SARS-CoV-2 virus and the consequent disease COVID-19 (1, 2, 3, 4, 5, 6). With highly targeted and SMDT regimens that include early application of antiviral drugs, combined with corticosteroids and anti-platelet/anti-thrombotic/anti-clotting therapeutics, the risk of hospitalization is significantly reduced by as much as by 85 to 90%, and risk of death is eliminated for high-risk patients and younger individuals presenting with severe symptoms.
COVID-19 presents as either a mild-flu-like condition (asymptomatic or mild symptoms) or more serious illness in those at high risk. A small fraction of persons infected with COVID virus progress to more serious illness (typically elderly with underlying medical conditions, obese or younger with underlying medical conditions/risks factors). The complex and multidimensional pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the illness.

As a brief background, the illness involves three phases 1) an initial viral replication phase whereby the virus hijacks the metabolic machinery of the cells which then begins to synthesize new viral particles ii) a more advanced inflammatory hyper-dysregulated immune-modulatory florid pneumonia phase whereby there is a cytokine storm and problematic gas exchange known as acute respiratory distress syndrome; ARDS. ARDS is generally the cause of most deaths attributed to COVID-19; and iii) a thrombotic blood clotting phase whereby microthrombi develop within the lungs and in the vasculature, leading to disastrous complications including profound hypoxemia, stroke, and heart attacks.

The ideal situation is to arrest the virus in the initial phase when symptoms have just emerged, while the patient is still within the home setting or extended care setting. The goal is to prevent hospitalization and death.

In countries where there is and was a reluctance to treat infected and symptomatic high-risk persons early, this therapeutic nihilism resulted in escalating symptoms, delayed in-hospital care and death. Fortunately, prompt and early initiation of SMDT is a widely and currently available solution to stem the tide of hospitalizations and death.

Viral illnesses such as COVID-19, with complex pathophysiology, do not respond to one drug treatment but require a multi-drug approach. We have to hit the virus with multiple therapeutics. This multipronged therapeutic approach includes 1) adjuvant nutritional supplements; 2) combination intracellular anti-infective therapy (antivirals and antibiotics); 3) inhaled/oral corticosteroids and colchicine; 4) antiplatelet agents/anticoagulants; 5) supportive care including supplemental oxygen, monitoring and telemedicine.

Randomized trials of individual, novel oral therapies have not delivered effective tools. No single therapeutic option thus far has been adequate, but combinations have been employed very successfully in clinical practice. Treating physicians who were courageous and brave felt it was urgent to apply the SMDT approach universally to benefit large numbers of acute COVID-19 patients, reducing their intensity and duration of symptoms and saving them from hospitalization and death. The key is use of early treatment as soon as symptoms develops when the virus is early in the replication phase.
This brief compilation (Table 1 and Figures 1 & 2) describes a cursory summary with the direct url links of therapeutics that have been shown some degree of effectiveness if infected with COVID-19 virus in any of its variant forms including Delta and Omicron.

While the COVID-19 emergency is winding down, with Omicron offering an exit off-ramp, variants, including the Delta and Omicron variant, still exist and will continue to. We therefore felt the public (and particularly those at high-risk) should be aware of known treatment options. While most people and especially young persons and children are indeed at very low risk of illness and especially from the very mild near ‘common-cold’ Omicron variant, this early treatment guidance provides an important resource that can be life saving when needed.

This piece covers:
Assisting with this article are
  • Dr. Paul E. Alexander, MSc, PhD (PublicHealth.news; TheUNITYProject)
  • Dr. Harvey Risch, MD, PhD (Yale School of Public Health)
  • Dr. Howard Tenenbaum, PhD ( Faculty of Medicine, University of Toronto)
  • Dr. Ramin Oskoui, MD (Foxhall Cardiology, Washington)
  • Dr. Peter McCullough, MD (Truth for Health Foundation (TFH)), Texas
  • Dr. Parvez Dara, MD (consultant, Medical Hematologist and Oncologist)
  • Mr. Erik Sass, MA (Editor at the Economic Standard)
[continued]
 

Heliobas Disciple

TB Fanatic
Well, that didn't work! Can't delete it either.

Trying again in pieces.


Table 1: Evidence on COVID early treatment therapeutics

Study #Author, study title, url link PDF, predominant summary finding on benefit of this drug in the armamentum of early treatment
Therapeutic’s name: IVERMECTIN (see Figure 1 and note on ivermectin for inpatient treatment as well as guidance for clinicians, please click here.)
1) Espitia-Hernandez G et al. “Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: a proof of concept study.” Biomedical Research 2020; 31 (5): 129-133Download PDFSummary: Patients who met inclusion criteria were invited to take Ivermectin (6 mg once daily in day 0,1,7 and 8) plus Azithromycin (500 mg once daily for 4 days) plus Cholecalciferol (4000 UI twice daily for 30 days). Treatment outcome was evaluated on the 10th day onward from the first day of the drug intake. Recovery rate of the 28 patients that received the combination therapy was 100%, the mean symptomatic recovery duration was 3.6 days and negative PCR was confirmed on day 10.
2) Samaha Ali et al. “Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.” Viruses 2021 May 26;13(6):989. Doi: 10.3390/v13060989Download PDFSummary: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose according to body weight of ivermectin, in addition to the same supplements the control group received. 72 hours after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. Additionally, more subjects in the control group developed clinical symptoms: three individuals (6%) required hospitalization, compared to 0% for the ivermectin group.
3) Cadegiani, FA et al. “Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.” New Microbes and New Infections, July 7, 2021. Doi: 10.1016/j.nmni.2021.100915Download PDFSummary: Compared to CG1 and CG2, AG showed a reduction of 31.5 to 36.5% in viral shedding (p < 0.0001), 70 to 85% and 70 to 73% in duration of COVID-19 clinical symptoms… For every 1,000 confirmed cases for COVID-19, a minimum of 140 patients were prevented from hospitalization (p < 0.0001), 50 from mechanical ventilation, and five deaths.
4) Biber A et al. “Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial.” medRxiv, May 31, 2021. Doi: 10.1101/2021.05.31.21258081Download PDFSummary: The double-blinded trial compared patients receiving ivermectin 0·2 mg/kg for 3 days vs. placebo in non-hospitalized COVID-19 patients… Primary endpoint was reduction of viral-load on the 6th day (third day after termination of treatment) as reflected by Ct level>30 (non-infectious level)… On day 6, 34 out of 47 (72%) patients in the ivermectin arm reached the endpoint, compared to 21/42 (50%) in the placebo arm… Cultures at days 2 to 6 were positive in 3/23 (13.0%) of ivermectin samples vs. 14/29 (48.2%) in the placebo group (p=0.008).
5) Merino J et al. “Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City.” SocArXiv, May 3, 2021. Doi: 10.31235/osf.io/r93g4Download PDFSummary: “We estimated logistic-regression models with matched observations adjusting by age, sex, COVID severity, and comorbidities. We found a significant reduction in hospitalizations among patients who received the ivermectin-based medical kit; the range of the effect is 52% – 76% depending on model specification.”
6) Fonseca SNS et al. “Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis.” Travel Med Infect Dis. 2020 November-December; 38. Doi: 10.1016/j.tmaid.2020.101906Download PDFSummary: “Use of hydroxychloroquine (HCQ), prednisone or both significantly reduced hospitalization risk by 50–60%. Ivermectin, azithromycin and oseltamivir did not substantially reduce risk further.”
7) Lima-Morales R et al. “Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.” Int J Infect Dis. 2021 Apr; 105: 598-605. Doi: 10.1016/j.ijid.2021.02.014Download PDFSummary: “A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18-80 years, who received ambulatory care… A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. The likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.”
8) Loué P et al. “Ivermectin and COVID-19 in Care Home: Case Report.” J Infect Dis Epidemiol. April 17, 2021; 7:4, 202. Doi: 10.23937/2474-3658/1510202Download PDFSummary: “Of the 25 PCR-positive patients, 10 chose to take the IVM treatment (group 1) and 15 chose not to take IVM (group 2). Patients of the group 1 received a single dose of 200 micrograms/kg body weight… Mortality occurred in 1 patient in the group 1 and 5 of the group 2 (p = 0.34).”
Therapeutic’s name: DOXYCYCLINE
1) Hashim H et al. “Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq.” medRxiv, October 27, 2020. Doi: 10.1101/2020.10.26.20219345Download PDFSummary: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2-3 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy… among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group.
2)Yates P et al. “Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.” Therapeutic Advances in Respiratory Disease. January 2020. Doi: 10.1177/1753466620951053Download PDFSummary: Case study of four high-risk, symptomatic COVID-19 patients who showed rapid improvement after treatment with doxycycline.
3)Ahmad I et al. “Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities.” medRxiv, May 22, 2020. Doi: 10.1101/2020.05.18.20066902Download PDFSummary: A series of 54 high-risk patients, who developed a sudden onset of fever, cough, and shortness of breath (SOB) and were diagnosed or presumed to have COVID-19, were started with a combination of DOXY-HCQ and 85% (n=46) patients showed clinical recovery defined as: resolution of fever and SOB, or a return to baseline setting if patients are ventilator-dependent. A total of 11% (n=6) patients were transferred to acute care hospitals due to clinical deterioration and 6% (n=3) patients died in the facilities. Naive Indirect Comparison suggests these data were significantly better outcomes than data reported in MMWR for comparable facilities.
4)Gendrot M et al. “In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.” Molecules, 2020, 25(21), 5064; Doi: 10.3390/molecules25215064Download PDFSummary: Doxycycline showed in vitro activity on Vero E6 cells infected with a clinically isolated SARS-CoV-2 strain (IHUMI-3) with median effective concentration (EC50) of 4.5 ± 2.9 µM, compatible with oral uptake and intravenous administrations. Doxycycline interacted both on SARS-CoV-2 entry and in replication after virus entry. Besides its in vitro antiviral activity against SARS-CoV-2, doxycycline has anti-inflammatory effects by decreasing the expression of various pro-inflammatory cytokines and could prevent co-infections and superinfections due to broad-spectrum antimicrobial activity.
5) Meybodi ZA et al. “Effectiveness and Safety Doxycycline in treating COVID-19 Positive Patients: A pilot clinical study.” Pakistan Journal of Medical and Health Sciences, June 2021; 15(1): 610-614. Doi: 10.21203/rs.3.rs-141875/v3Download PDFSummary: Patients who met the inclusion criteria received doxycycline at a dose of 100 mg every 12 hours for seven days and then were evaluated on the baseline day. On days 3, 7, and 14 after admission for cough, shortness of breath, temperature, and oxygen saturation. Finding: Out of 21 patients, 11 patients were male, and ten patients were female. Cough, shortness of breath, temperature, and O2 sat improved in both outpatients and inpatients compared to baseline.
 

Heliobas Disciple

TB Fanatic
Therapeutic’s name: VITAMIN D
1)Kaufman H et al. “SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels.” PLOS One, September 17, 2020. Doi: 10.1371/journal.pone.0239252Download PDFSummary: Retrospective, observational analysis to determine if circulating 25-hydroxyvitamin D (25(OH)D) levels are associated with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) positivity rates. A total of 191,779 patients were included, median age 54 years, 68% female. The SARS-CoV-2 positivity rate was higher in the 39,190 patients with “deficient” 25(OH)D values (<20 ng/mL) (12.5%, 95% C.I. 12.2–12.8%) than in the 27,870 patients with “adequate” values (30–34 ng/mL) (8.1%, 95% C.I. 7.8–8.4%) and the 12,321 patients with values ≥55 ng/mL (5.9%, 95% C.I. 5.5–6.4%).
2)Israel A et al. “The link between vitamin D deficiency and Covid-19 in a large population.” medRxiv, September 7, 2020. Doi: 10.1101/2020.09.04.20188268Download PDFSummary: Population-based study to assess the relationship between prevalence of vitamin D deficiency and COVID-19 incidence. Matched 52,405 infected patients with 524,050 control individuals of the same sex, age, geographical region and used conditional logistic regression to assess the relationship between baseline vitamin D levels, acquisition of vitamin D supplements in the last 4 months, and positive COVID-19. Found highly significant correlation between prevalence of vitamin D deficiency and COVID-19 incidence, and between female-to-male ratio for severe vitamin D deficiency and female-to-male ratio for COVID-19 incidence. In the matched cohort, found significant association between low vitamin D levels and the risk of COVID-19, with the highest risk observed for severe vitamin D deficiency. A significant protective effect was observed for members who acquired liquid vitamin D formulations (drops) in the last 4 months.
3)Katz J. “Increased risk for COVID-19 in patients with vitamin D deficiency.” Nutrition, 2021 Apr; 84:111106. Doi: 10.1016/j.nut.2020.111106Download PDFSummary: Patients with vitamin D deficiency were 4.6 times more likely to be positive for COVID-19 (indicated by the ICD-10 diagnostic code COVID19) than patients with no deficiency (P < 0.001). In addition, patients with vitamin D deficiency were 5 times more likely to be infected with COVID-19 than patients with no deficiency after adjusting for age groups (OR = 5.155; P < 0.001).
4)Baktash V et al. “Vitamin D status and outcomes for hospitalised older patients with COVID-19.” Postgrad Med J. 2021 Jul;97(1149):442-447. Doi: 10.1136/postgradmedj-2020-138712Download PDFSummary: Prospective cohort study between 1 March and 30 April 2020 to assess the importance of vitamin D deficiency in older patients with COVID-19. The cohort consisted of patients aged ≥65 years presenting with symptoms consistent with COVID-19 (n=105). COVID-19-positive arm demonstrated lower median serum 25(OH)D level of 27 nmol/L (IQR=20-47 nmol/L) compared with COVID-19-negative arm, with median level of 52 nmol/L (IQR=31.5-71.5 nmol/L) (p value=0.0008). Among patients with vitamin D deficiency, there was higher peak D-dimer level (1914.00 μgFEU/L vs 1268.00 μgFEU/L) (p=0.034) and higher incidence of NIV support and high dependency unit admission (30.77% vs 9.68%) (p=0.042).
5) Martín Giménez VM et al. “Vitamin D deficiency in African Americans is associated with a high risk of severe disease and mortality by SARS-CoV-2.” Journal of Human Hypertension vol 35, pages 378–380 (2021). Doi: 10.1038/s41371-020-00398-zDownload PDFSummary: Despite the lack of studies to define the adequate level of vitamin D to protect against viral infection, we agree with Grant et al., and estimate that a range between 40 and 60 mg/dL and the recommended dose to achieve this, between 5000 and 10,000 IU/day for several weeks.
6)Ricci A et al. “Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients.” Respiratory Research vol 22, Article number: 76 (2021). Doi: 10.1186/s12931-021-01666-3Download PDFSummary: Vitamin D levels were deficient in (80%) of patients, insufficient in (6.5%) and normal in (13.5%). Patients with very low Vitamin D plasma levels had more elevated D-Dimer values, a more elevated B lymphocyte cell count, a reduction of CD8 + T lymphocytes with a low CD4/CD8 ratio, more compromised clinical findings (measured by LIPI and SOFA scores) and thoracic CT scan involvement. Vitamin D deficiency is associated with compromised inflammatory responses and higher pulmonary involvement in COVID-19 affected patients.
7)Lakkireddy M et al. “Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.” Scientific Reports vol 11, May 20, 2021. Doi: 10.1038/s41598-021-90189-4Download PDFSummary: Therapeutic improvement in vitamin D to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects.
Therapeutic’s name: ZINC
1)Carlucci P et al. “Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.” Journal of Medical Microbiology, September 15, 2020, v 69 issue 10. Doi: 1099/jmm.0.001250Download PDFSummary: In univariate analyses, zinc sulphate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU and mortality or transfer to hospice for patients who were never admitted to the ICU.
2)Dubourg G et al. “Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?” Journal of Microbiology, Immunology and Infection, February 13, 2021. 1016/j.jmii.2021.01.012Download PDFSummary:Among 275 patients with COVID-19, we found that median blood zinc level was significantly lower in patients with poor clinical outcome (N=75) as compared to patients with good clinical outcome (N=200) (840 μg/L versus 970 μg/L; p< 0.0001), suggesting that zinc supplementation could be useful for patients with severe COVID-19.
3)Frontera J et al. “Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study.” BMC Infectious Diseases [preprint]. October 26, 2020. Doi: 21203/rs.3.rs-94509/v1Download PDFSummary: Among 3,473 patients (median age 64, 1947 [56%] male, 522 [15%] ventilated, 545[16%] died), 1,006 (29%) received Zn+ionophore. Zn+ionophore was associated with a 24% reduced risk of in-hospital mortality (12% of those who received Zn+ionophore died versus 17% who did not).
4)Heller RA et al. “Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.” Redox Biology, January 2021, v 38. Doi: 1016/j.redox.2020.101764Download PDFSummary: Our data indicate a profound and acute zinc deficiency in the majority of patients with COVID-19 when admitted to the hospital. … We conclude that Zn and SELENOP status within the reference ranges indicate high survival odds in COVID-19, and assume that correcting a diagnostically proven deficit in Se and/or Zn by a personalised supplementation may support convalescence.
5)Vogel-González M et al. “Low zinc levels at clinical admission associates with poor outcomes in COVID-19.” medRxiv, October 11, 2020. Doi: 1101/2020.10.07.20208645Download PDFSummary: Individuals with SZC at admission <50 µg/dl had a mortality of 21% that was significantly higher compared with 5% mortality in individuals with zinc at admission ≥50 µg/dl; p<0·001. Our study demonstrates a correlation between serum zinc levels and COVID-19 outcome. Serum zinc levels lower than 50 mcgg/dl at admission correlated with worse clinical presentation, longer time to reach stability and higher mortality.
6)Jothimani D et al. “COVID-19: Poor outcomes in patients with zinc deficiency.” International Journal of Infection Diseases, November 2020, v 100: 343-349. Doi: 1016/j.ijid.2020.09.014Download PDFSummary: More patients in the Zinc deficient group … required ICU care (7 vs 2, P=0.266) and recorded deaths (5 vs 0) in comparison to patients with normal Zinc levels.
7)Yasui Y et al. “Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19.” International Journal of Infectious Diseases, November 2020, v 100: 230-236. Doi: 1016/j.ijid.2020.09.008Download PDFSummary:Based on the measurement results of serum zinc levels in patients with COVID-19 in our hospital, almost all severe cases showed subclinical or clinical zinc deficiency. Prolonged hypozincemia was found to be a risk factor for a severe case of COVID-19. In evaluating the relationship between the serum zinc level and severity of patients with COVID-19 by multivariate logistic regression analysis, critical illness can be predicted through the sensitivity and false specificity of an ROC curve with an error rate of 10.3% and AUC of 94.2% by only two factors: serum zinc value (P = 0.020) and LDH value (P = 0.026).
8)Derwand R et al. “COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.” International Journal of Antimicrobial Agents, December 2020, v 56:6. Doi: 1016/j.ijantimicag.2020.106214Download PDFSummary: After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-67; 73% male) received a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p<0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.12).
 

Heliobas Disciple

TB Fanatic
Therapeutic’s name: COLCHICINE
1)Tardif JC et al. “Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.” Lancet Respir Med. 2021 May 27; Doi: 10.1016/S2213-2600(21)00222-8Download PDFSummary: 2,235 patients were randomly assigned to colchicine and 2,253 to placebo. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo.
2)Scarsi M et al. “Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.” Ann Rheum Dis. 2020 Oct; 79(10): 1286–1289. Doi: 10.1136/annrheumdis-2020-217712Download PDFSummary: 140 consecutive inpatients were treated with standard of care (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients treated with colchicine and standard of care (antiviral drugs were stopped before colchicine, due to potential interaction). Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% vs 63.6%).
Therapeutic’s name: BROMHEXINE
1)Ansarin et al. “Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.” BioImpacts, 2020, 10(4), 209-215. Doi: 10.34172/bi.2021.30Download PDFSummary: A total of 78 patients with similar demographic and disease characteristics were enrolled. There was a significant reduction in ICU admissions (2 out of 39 vs. 11 out of 39, P=0.006), intubation (1 out of 39 vs. 9 out of 39, P=0.007) and death (0 vs. 5, P=0.027) in the bromhexine treated group compared to the standard group. No patients were withdrawn from the study because of adverse effects.
2)Li et al. “Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study.” Clin. Transl. Sci (2020) 13, 1096–1102. Doi: 10.1111/cts.12881Download PDFSummary: A total of 18 patients with moderate COVID-19 were randomized into the BRH group (n = 12) or the control group (n = 6). There were suggestions of BRH advantage over placebo in improved chest computed tomography, need for oxygen therapy, and discharge rate within 20 days.
3)Maggio et al. “Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.” Pharmacological Research 157 (July 2020) 104837 Doi: 10.1016/j.phrs.2020.104837Summary: Pharmacokinetic data support the testing of bromhexine use for this indication since, in pulmonary and bronchial epithelial cells, it may reach concentrations 4 to 6-fold higher than those found in the plasma, high enough in principle to inhibit TMPRSS2.
4)Mareev, et al. “Results of an open, prospective, controlled, comparative study for the treatment of novel coronavirus infection (COVID-19): Bromhexine
And Spironolactone for the treatment of Corona Viral Infection Requiring Hospitalization (BISQUIT).” Kardiologiia, 2020;60(11). DOI: 10.18087/cardio.2020.11.n1440English translation: Results of Open-Label non-Randomized Comparative Clinical Trial: "BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT) - PubMedDownload PDFSummary: 103 patients were included (33 in the bromhexine and spironolactone group and 70 in the control group). Analysis for the group as a whole revealed a statistically significant reduction in hospitalization time from 10.4 to 9.0 days and fever time from 6.5 to 3.9 days.
5)Mikhaylov, et al. “Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study.” medRxiv preprint, May 29, 2021. Doi: 10.1101/2021.03.03.21252855Download PDFSummary: 25 healthcare workers were assigned to bromhexine hydrochloride treatment (8 mg 3 times per day), and 25 were controls. Fewer participants developed symptomatic COVID-19 in the treatment group compared to controls (0/25 vs 5/25).
6)Ou, et al. “Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.” PLOS Pathogens, January 19, 2021. Doi: 10.1371/journal.ppat.1009212Download PDF (from PLOS website)Summary: We show that combinations of hydroxychloroquine and a clinically tested TMPRSS2 inhibitor work together to effectively inhibit SARS-CoV-2 entry.
Therapeutic’s name: BUDESONIDE
1)Ramakrishnan S et al. “Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.” Lancet Respir Med, April 9, 2021. Doi: 10.1016/ S2213-2600(21)00171-5Download PDFSummary: 146 participants were randomly assigned, 73 to usual care and 73 to budesonide. For the per-protocol population (n=139), the primary outcome occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group. For the ITT population, the primary outcome occurred in 11 (15%) participants in the usual care group and two (3%) participants in the budesonide group. Clinical recovery was 1 day shorter in the budesonide group compared with the usual care group (median 7 days versus 8). The mean proportion of days with a fever in the first 14 days was lower in the budesonide group than the usual care group (2% versus 8%) and the proportion of participants with at least 1 day of fever was lower in the budesonide group when compared with the usual care group. Fewer participants randomly assigned to budesonide had persistent symptoms at days 14 and 28.
Therapeutic’s name: DEXAMETHASONE
1)Tomazini BM et al. “Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19The CoDEX Randomized Clinical Trial.” JAMA, September 2, 2020. Doi: 10.1001/jama.2020.17021Download PDFSummary: In this randomized clinical trial that included 299 patients, the number of days alive and free from mechanical ventilation during the first 28 days was significantly higher among patients treated with dexamethasone plus standard care when compared with standard care alone (6.6 days vs 4.0 days).
2)Horby P et al. (RECOVERY Collaborative). “Dexamethasone in Hospitalized Patients with COVID-19.” NEJM, February 25, 2021. Doi: 10.1056/NEJMoa2021436Download PDFSummary: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
 

Heliobas Disciple

TB Fanatic
Therapeutic’s name: MONOCLONAL ANTIBODIES
1)Verderese JP et al. “Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.” Clinical Infectious Diseases, June 24, 2021. Doi: 10.1093/cid/ciab579Download PDFSummary: 707 confirmed COVID-19 patients received NmAbs and 1709 historic COVID-19 controls were included; 553 (78%) received BAM, 154 (22%) received REGN-COV2. Patients receiving NmAb infusion had significantly lower hospitalization rates (5.8% vs 11.4%, P < .0001), shorter length of stay if hospitalized (mean, 5.2 vs 7.4 days; P = .02), and fewer ED visits within 30 days post-index (8.1% vs 12.3%, P = .003) than controls.
2)O’Brien MP et al. “Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.” NEJM, August 4, 2021. Doi: 10.1056/NEJMoa2109682Download PDFSummary: Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P<0.001). In weeks 2 to 4, a total of 2 of 753 participants in the REGEN-COV group (0.3%) and 27 of 752 par- ticipants in the placebo group (3.6%) had symptomatic SARS-CoV-2 infection (relative risk reduction, 92.6%). REGEN-COV also prevented symptomatic and asymptomatic infections overall (relative risk reduction, 66.4%). Among symptomatic infected par- ticipants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV than with placebo (1.2 weeks and 3.2 weeks, respectively), and the duration of a high viral load (>104 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted.
Therapeutic’s name: QUERCETIN
1)Di Pierro F et al. “Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study.” Int J General Med, June 8, 2021. Doi: 10.2147/IJGM.S318720Download PDFSummary: Prospective, randomized, controlled, and open-label study. Daily dose of 1000 mg of QP was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease. The results revealed a reduction in frequency and length of hospitalization, in need of non-invasive oxygen therapy, in progression to intensive care units and in number of deaths. The results also confirmed the very high safety profile of quercetin.
Therapeutic’s name: FLUVOXAMINE
1)Lenze E et al. “Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19. A Randomized Clinical Trial.” JAMA. 2020; 324(22): 2292-2300. Doi: 10.1001/jama.2020.22760Summary: In this randomized trial that included 152 adult outpatients with confirmed COVID-19 and symptom onset within 7 days, clinical deterioration occurred in 0 patients treated with fluvoxamine vs 6 (8.3%) patients treated with placebo over 15 days, a difference that was statistically significant.
2)Reis G et al. “Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.” Lancet Global Health. October 27, 2021; 10(1): E42-E51. Doi: 10.1016/S2214-109X(21)00448-4Summary: The proportion of patients observed in a COVID-19 emergency setting for more than 6 h or transferred to a teritary hospital due to COVID-19 was lower for the fluvoxamine group compared with placebo (79 [11%] of 741 vs 119 [16%] of 756) [. . .] There were 17 deaths in the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR] 0·68, 95% CI: 0·36–1·27). There was one death in the fluvoxamine group and 12 in the placebo group for the per-protocol population (OR 0·09; 95% CI 0·01–0·47).
3)Seftel D et al. “Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.” Open Forum Infectious Diseases, Volume 8, Issue 2, February 2021. Doi: 10.1093/ofid/ofab050Download PDFSummary: Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Therapeutic’s name: PREDNISONE
1)Ooi ST et al. “Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.” Travel Open Forum Infectious Diseases, Volume 7, Issue 11, November 2020, ofaa486. Doi: 10.1093/ofid/ofaa486Download PDFSummary: “A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.”
2)Fonseca SNS et al. “Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis.” Travel Med Infect Dis. 2020 November-December; 38. Doi: 10.1016/j.tmaid.2020.101906Download PDFSummary: “Use of hydroxychloroquine (HCQ), prednisone or both significantly reduced hospitalization risk by 50–60%.”
Therapeutic’s name: AZITHROMYCIN
1)Taieb F et al. “Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020.” J Clin Med, 2021 Jun 30;10(13):2954. Doi: 3390/jcm10132954.Download PDFSummary: A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63, IC 95% (1.09-2.43).
2)Lagier JC et al. “Outcomes of 2,111 COVID-19 hospitalised patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a monocentric retrospective analysis.” IHU-Méditerranée Infection [preprint], June 4, 2021.Download PDFSummary: Treatment with HCQ-AZ was an independent protective factor against death – Zinc was independently protective against death in patients treated with HCQ-AZ.
3)Heras E et al. “COVID-19 mortality risk factors in older people in a long-term care center.” European Geriatric Medicine, November 27, 2020, v 12, p 601–607. Doi: 1007/s41999-020-00432-wDownload PDFSummary: Among 100 COVID-19+ nursing home patients in Andorra, multivariate logistic regression analysis identified hydroxychloroquine plus azithromycin treatment as an independent factor favoring survival compared with no treatment or other treatments.
4)Ly TDA et al. “Pattern of SARS-CoV-2 infection among dependent elderly residents living in long-term care facilities in Marseille, France, March-June 2020.” Int J Antimicrob Agents, 2020 Dec;56(6):106219. Doi: 1016/j.ijantimicag.2020.106219Summary: Data from 1,691 elderly residents and 1,000 members of staff were retrospectively collected through interviewing the medical teams in 24 LTCFs and using the hospitals’ electronic health recording systems. 116 (51.4%) patients received a course of oral hydroxychloroquine and azithromycin (HCQAZM) for ≥3 days, and 47 (20.8%) died. Through multivariate analysis, the death rate was positively associated with being male (30.7%, vs. 14.0%, OR=3.95, p=0.002), being older than 85 years (26.1%, vs. 15.6%, OR=2.43, p=0.041), and receiving oxygen therapy (39.0%, vs. 12.9%, OR=5.16, p<0.001) and negatively associated with being diagnosed through mass screening (16.9%, vs. 40.5%, OR=0.20, p=0.001) and receiving HCQ-AZM treatment ≥3 days (15.5%, vs. 26.4%, OR=0.37, p=0.02).
5)Lauriola M et al. “Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients.” Clinical and Translational Science, September 14, 2020. Doi: 1111/cts.12860Download PDFSummary: In this study, we found a reduced in‐hospital mortality in patients treated with a combination of hydroxychloroquine and azithromycin after adjustment for comorbidities. … At multivariable Cox proportional hazard regression analysis, … use of hydroxychloroquine + azithromycin (vs. no treatment) (HR 0.265, 95%CI 0.171‐0.412, p<0.001) was inversely associated [with death].
6)Arshad S et al. “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.” Int Jour Inf Dis, July 1, 2020, 97: 396-403. Doi: 10.1016/j.ijid.2020.06.099Download PDFSummary: In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality.
 

Heliobas Disciple

TB Fanatic
Therapeutic’s name: HYDROXYCHLOROQUINE (Figure 2)
1)Risch, Harvey. “Hydroxychloroquine in Early Treatment of High-Risk COVID-19 Outpatients: Efficacy and Safety Evidence.” Sixth version, updated June 17, 2021.Download PDFSummary: Every study of high-risk outpatient hydroxychloroquine (HCQ) use has shown risk reduction for hospitalization or mortality. Meta-analysis demonstrates 40% reduction in hospitalization and 75% reduction in mortality. A large database study of more than 900,000 older patients taking hydroxychloroquine shows no excess all-cause mortality and no excess occurrence of fatal cardiac arrhythmia.
2)Million M et al. “Early treatment with hydroxychloroquine and azithromycin in 10,429 COVID-19 outpatients: A monocentric retrospective cohort study.” Accepted for publication, Int J Infect Dis.Download PDFSummary: Cohort of 10,429 COVID-19 patients treated with HCQ, azithromycin and other medications. Among patients age 60 and older, 1,495 patients treated with HCQ+azithromycin for 3+ days were compared to 520 patients given the medications for less than 3 days, or given only the individual medications, or not given either one. The age, sex and time-period adjusted-regression analysis showed a mortality odds ratio of 0.17.
3)Mokhtari M et al. “Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. Int Immunopharmacol Vol 96, July 2021. Doi: 10.1016/j.intimp.2021.107636Download PDFSummary: Multicenter, population-based national retrospective-cohort investigation of 28,759 adults with mild COVID-19 seen within 7 days of symptom onset between March and September 2020 in Iran. Treatment with HCQ was associated with a 38% reduction in risk of hospitalization and a 70% reduction in mortality risk, both highly statistically significant.
4)Barbosa Esper, et al. “Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine.” April 15, 2020. Accessed April 30, 2020.Download PDFSummary: Even though the severities of symptoms and comorbidities were substantially greater in the treated patients than the controls, the need for hospitalization was significantly lower among those receiving hydroxychloroquine: 1.2% in patients starting treatment before day 7 of symptoms and 3.2% for patients starting treatment after day 7, compared to 5.4% for controls. No cardiac arrhythmias were reported in the 412 treated patients.
5)Szente Fonseca SN et al. “Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis.” Travel Med Infect Dis 2020;38:101906. Doi: 10.1016/j.tmaid.2020.101906Download PDFSummary: Study of 717 tested-positive symptomatic patients over age 40, mean age 51, presenting between May 11 and June 3, 2020 in Brazil. Adjusted for age, gender, dyspnea at presentation, obesity, diabetes, and heart disease, use of both HCQ and prednisone together was associated with an odds ratio for hospitalization of 0.40; use of HCQ only, odds ratio=0.45; and use of prednisone only, odds ratio=0.51.
6)Ip A et al. “Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. BMC Infect Dis 2021;21:72. Doi: 10.1186/s12879-021-05773-wDownload PDFSummary: Between March 1 and April 22, 2020, 1,274 patients with non-admission ER visits were identified and confirmed infected with SARS-CoV-2 by PCR testing. 97 received prescriptions for or had started taking HCQ, and from the remaining 1,177, 970 were propensity-score matched by age, demographic variables and a host of comorbidity factors, presenting symptoms, indicators of disease severity, baseline laboratory tests, and ER-visit and follow-up times. More than three-quarters of the subjects had comorbidities or were over age 60, making them high-risk. In the matched multivariate analysis, treatment with HCQ significantly cut the risk of hospitalization by 47%.
7)Ly TDA et al. “Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020.” Int J Antimicrob Agents 2020;56(6):106219. Doi: 10.1016/j.ijantimicag.2020.106219Download PDFSummary: Study of 23 nursing homes in Marseille, France in which of 226 infected residents, 37 were detected because of COVID-19 symptoms and 189 through mass screening. In multivariate analysis adjusted for sex, age, use of oxygen therapy and detection modality (symptoms vs screening), receipt of HCQ+azithromycin for at least three days was associated with 63% reduced mortality risk.
8)Heras E et al. “COVID-19 mortality risk factors in older people in a long-term care center.” Eur Geriatr Med 2021;12(3):601-607. Doi: 10.1007/s41999-020-00432-wDownload PDFSummary: Study identified 100 PCR-confirmed COVID-19 patients, median age 85, who received HCQ+azithromycin, HCQ with other antibiotics such as beta-lactam or quinolone types, or other antibiotics alone. In multivariate analysis of risk-adjusted mortality, treatment with HCQ+azithromycin vs. only other antibiotics had OR=0.044; treatment with HCQ+other antibiotics vs. other antibiotics alone had OR=0.32.
9)Cangiano B et al. “Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests.” Aging 2020;12. Doi: 10.18632/aging.202307Download PDFSummary: Ninety-eight of 157 residents in a nursing home in Milan, Italy, average age 90, tested positive for SARS-CoV-2. In logistic regression models adjusted for age, sex, Barthel’s index and BMI, receipt of HCQ was associated with 7-fold reduced mortality.
10)Sulaiman T et al. “The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study.” Preprints 2020. Doi: 10.1101/2020.09.09.20184143Download PDFSummary: Roughly 8,000 mild-moderate cases of PCR-positive COVID-19 presenting at national outpatient treatment clinics in Saudi Arabia between 5-26 June, 2020 were recruited for enrollment. Treated and control patients were comparable in distributions of age, sex and nine comorbidities reported. In multivariate modeling adjusted for age, gender and comorbidities, HCQ receipt cut mortality 3-fold, while there was a 5-fold reduction in mortality with HCQ+zinc treatment vs zinc only.
11)Cadegiani, FA et al. “Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.” New Microbes and New Infections, July 7, 2021. Doi: 1016/j.nmni.2021.100915Download PDFSummary: In total, 159 patients were treated with HCQ and 137 controls participated. There were no hospitalizations or deaths among the HCQ patients, whereas 27 control patients were hospitalized and 2 died.
 

Heliobas Disciple

TB Fanatic
Figure 1: Studies of ivermectin as an outpatient treatment

image1-4-682x800.jpg


Figure 2: Studies of hydroxychloroquine as an outpatient treatment

image2-2-538x800.jpg


[end article; thank you to Profit of Doom who asked me to post it]
 
Top